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Clinical development of prophylactic HIV/AIDS vaccines presents many scientiﬁc challenges that result in
challenges for regulators reviewing clinical trial applications (CTAs). The World Health Organization
(WHO) has the responsibility to provide technical support to these regulators. The search for an HIV/AIDS
vaccine will only succeed through well-designed, -conducted and -controlled human efﬁcacy studies
reviewed and approved by regulators in countries worldwide, particularly in countries where the
epidemic has hit hardest, such as in sub-Saharan Africa and Asia. This review summarizes the current
candidates in development and focuses on challenges regulators face when reviewing CTAs, such as the
evolving landscape of “standard of prevention,” trials in adolescents, adaptive trial designs, correlates of
protection and their analysis, and access to successful vaccines. There are many unknowns in the ﬁeld of
HIV/AIDS vaccine development and often, there is not a clear right or wrong approach because of the
scientiﬁc challenges described in this review. Consequently, regulators should not feel that decisions
need be made in isolation, when there are many available international collaborative efforts and op-
portunities to seek expert advice. The WHO provides many such opportunities and support to regulators
across the globe.
© 2016 The Authors. Published by Elsevier Ltd on behalf of The International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction e scope and purpose of review
Currently, the development of experimental preventive Human
Immunodeﬁciency Virus Type 11 (HIV) vaccines includes a wide
variety of innovative and complex approaches without precedent in
other, licensed vaccines. International harmonization and stan-
dardization of regulatory practices will help to ensure that HIV
vaccines are evaluated and licensed based on internationally
accepted scientiﬁc criteria and standards. However, there are no
international guidelines speciﬁc for the evaluation of HIV vaccines(R.L. Sheets), zhout@who.int
S were used and referred to
wledge, few, if any efforts are
his review is strictly conﬁned
Ltd on behalf of The International A
by-nc-nd/4.0/).available, though a wide range of guidelines covering various as-
pects such as the production and quality control, nonclinical and
clinical evaluation of biological products are available from WHO
and UNAIDS and other international or national regulatory bodies
(International Conference on Harmonisation e ICH, Food and Drug
Administration e US FDA, and the European Medicines Agency e
EMA; see Tables 1 and 2 in Appendix 1). Many of the principles are
applicable to HIV vaccines. The new approaches that are being
taken for HIV/AIDS vaccine development, e.g., vectored vaccines or
heterologous prime-boost immunization, are not adequately
covered by existing guidelines. Speciﬁc guidance and technical
support are therefore, required to help regulators from all coun-
tries, particularly those in low- and middle-income countries
(LMIC), understand the scientiﬁc rationale and challenges for HIV
vaccine development and regulatory evaluation in order to build
technical expertise for HIV vaccine evaluation and licensure.
Prophylactic HIV vaccine clinical trials, including efﬁcacy trials,
have been conducted worldwide. Many of the countries hardest hitlliance for Biological Standardization. This is an open access article under the CC BY-
2 Many HIV/AIDS vaccine candidates actually consist of complex regimens,
termed prime-boost regimens, in which more than one immunogen may be given
at the same or separate times, e.g., three primes with a DNA plasmid followed by a
viral vector boost or primes with a poxvirus vector followed by boosts with a
combination of poxvirus vector and proteins. Throughout the review, reference to
vaccine or vaccine candidates or regimens will mean whatever complex regimen is
proposed in a particular HIV vaccine clinical protocol rather than a single candidate
immunogen as might be used in other diseases, e.g., measles.
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are in sub-Saharan Africa or Asia and most of those are LMIC or
emerging market countries. Regulation of clinical trials in many
LMIC, in which some HIV vaccine clinical trials are taking place, is
still new and evolving. In some countries, regulators are primarily
pharmacists and often they have more of a pharmaceutical back-
ground and are less experienced with vaccines or biologicals.
Although they have extensive experience with registration of drugs,
regulation of clinical trials of unlicensed biologicals, like HIV/AIDS
vaccine candidates, can be more challenging. LMIC regulators often
have experiencewith registration of vaccines that are included in the
WHO Expanded Programme for Immunization (EPI) or certain other
key vaccines relevant to their populations (e.g., malaria ormeningitis
A), but HIV/AIDS vaccine candidates differ in several key facets from
childhood vaccines that have been in use for decades. However, LMIC
regulators are gaining experience with HIV/AIDS clinical trial re-
views and evaluation because of the number of clinical trials that
have been conducted to date. With this experience comes the
recognition that there are aspects of regulating HIV/AIDS clinical
trials, borne from the scientiﬁc challenges and gaps in knowledge,
which are not only challenging for regulators, but may create bar-
riers to vaccine development and evaluation. It is these aspects that
will be the focus of this and the companion review.
It should also be acknowledged that each country has its own
legal framework that invests the regulators of that country with
authority to oversee clinical trial authorization. Some countries do
not have such legislation, and only drug registration is the legal
authority of regulators. This diversity in legal frameworks poses
an additional challenge to regulators in various countries, as well
as to applicants who wish to work in a country in compliance with
the law and established ethical principles. It should go without
stating that a population for a clinical trial should not be chosen
on the basis of a lack of legal authority for regulatory oversight of
clinical trials in that country, but instead selected on the basis of
established cohorts of HIV-at-risk populations who have the po-
tential to beneﬁt from the trial. In cases where the regulators do
not have sufﬁcient legal authority, trial sponsors/applicants
should consider strongly engaging the WHO in trial review,
through one of their advisory committees or through the Article
58 procedure, as well as informing in some manner, the local
regulatory agency of their plans. In all cases, local ethics com-
mittees should have oversight.
Many of the aspects that challenge regulators reviewing HIV/
AIDS vaccine clinical trial protocols were requested to be addressed
in queries to WHO from regulators, manufacturers and vaccine
developers. In particular, information regarding the status of the
most promising/most advanced HIV vaccine candidates, appro-
priate methods for their evaluation and guiding principles that are
applicable to speciﬁc vaccine formulations and their intended use
were part of frequently asked questions. It will be important for
regulators to distinguish between issues relevant to Phase 1 and 2
trials, which are not intended to address efﬁcacy, but only pre-
liminary safety and activitymeasures, from review issues speciﬁc to
Phase 2b and Phase 3 trials, intended to demonstrate efﬁcacy, and
which may form the basis for ultimate licensure decisions.
2. Scientiﬁc challenges that create regulatory challenges for
HIV/AIDS vaccine development
The scientiﬁc challenges faced by HIV/AIDS vaccine develop-
ment are innumerable and have been reviewed many times over
[1e9]. Nonetheless, from the perspective of regulators tasked with
reviewing vaccine clinical trial applications (CTA), there are some
scientiﬁc challenges that warrant reiteration, as they result in
regulatory challenges.2.1. Lack of human survivors
Often, empirical development of a vaccine starts by evaluation
of the types and magnitudes of immune responses elicited in
humans who survived the infection or disease (convalescents) or
who clinically managed well the infectious organism to which a
vaccine is sought. By understanding the immune responses in in-
dividuals who did well despite infection, one has a target response
to aim a vaccine to meet. However, human survivors (“cures”) of
HIV infections consist only of case studies, like the stem cell
transplant recipient known as the “Berlin patient” [10]. These
anecdotal case studies rarely result from a strictly immunological
clearance of infection, but represent medical interventions with
rare and extraordinary success. Simply put, once infected with HIV,
the best that can be hoped at present is that the disease will be
chronically managed with anti-retroviral and other therapies.
There are no descriptions of immunologically-produced survivors
from infection. So, there is no clear immunological target for how
to prevent infection or disease. Thus, regulators, when faced with
the review of immunological data for a candidate vaccine, have no
greater insight than any other scientist in the HIV/AIDS vaccine
ﬁeld as to whether those data actually support advancing the
candidate further in clinical studies. At best, a regulator must judge
whether the candidate vaccine or regimen2 elicits the types of
immune responses that the applicant claims to be the mode-of-
action for the vaccine. Judging whether that claim of the mode-
of-action may actually result in efﬁcacy is not truly possible at
present.2.2. Lack of predictive animal model of efﬁcacy
The next step in the development of a successful vaccine, after
identifying what the target immune response to vaccination
should be, is often to attempt to protect from an infectious chal-
lenge in an animal model using a candidate vaccine. Although
there exist several animal models of HIV/AIDS that have yielded
signiﬁcant insight into HIV disease pathogenesis and other sci-
entiﬁc insights, none have yet been fully predictive of the out-
comes seen in the human efﬁcacy studies performed to-date. In
fact, each efﬁcacy study performed in humans has had some
supportive animal data suggesting efﬁcacy would be seen, but in
the end, the human efﬁcacy study results were unpredictable and
unpredicted by the animal data. One NHP model used in studies
performed after the conclusion of RV144 was able to recapitulate
the ﬁndings [11]. Whether this model will help predict future
successful candidates remains unknown. For regulators, this
means that the requirement of particular animal models to sup-
port clinical advancement of a candidate vaccine or candidate
regimen would be an unreasonable expectation. While some an-
imal data are needed to verify safety and activity (immunoge-
nicity), challengeeprotection models may be misleading and
should be interpreted with signiﬁcant caution. Such models may
provide insight into a potential mechanism or mode-of-action, but
cannot be taken to predict success of a candidate vaccine or
regimen in humans.
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As a result of the two challenges described in Sections 2.1 and
2.2, the lack of human survivors and the lack of a predictive ani-
mal model for efﬁcacy, immune correlates of protection remain
poorly understood and poorly deﬁned. Some data have emerged
from the single efﬁcacy study in which modest efﬁcacy was ach-
ieved and these are discussed in the companion review and else-
where [1,12]. Whether those potential correlates will hold true for
other candidates or regimens or even be substantiated with similar
regimens or highly related candidates, when studied in other
populations of higher incident infection rates or infected by
different routes of transmission or infected with different clades of
HIV, remains to be tested. Plans are underway to do just that. Other
vaccines have been licensed without identifying a deﬁnitive
correlate of protection, e.g., although Human Papillomavirus (HPV)
vaccine efﬁcacy correlates with antibodies, the high efﬁcacy seen in
efﬁcacy trials precluded identifying a level of antibodies below
which efﬁcacy was not established, i.e., an actual correlate. Like-
wise, pertussis vaccines, tuberculosis vaccine and rotavirus vac-
cines have all been licensed without deﬁnitively identifying the
type or geometric mean titer (or concentration) of antibody (or
immunological) responses required for protection. In the case of
HIV/AIDS vaccines, not only is the type or titer of antibody needed
undeﬁned or the epitope target of such antibodies uncertain, it is
unclear whether antibodies alone will be sufﬁcient or if various
types of T cell responses, or even innate immune responses, may
also be required to achieve efﬁcacy with a particular candidate or
regimen. Likewise, it is unclear whether “sterilizing” immunity will
need to be achieved or whether it might be possible for a successful
immune response generated by a vaccine to abort an infection, i.e.,
whether transient infection that is cleared could be a clinically
meaningful beneﬁt to target.
For regulators, this makes review of the design of certain types
of vaccine clinical trials more challenging, e.g., bridging studies,
comparability or non-inferiority studies (e.g., lot consistency
studies or clinical studies to support changes to manufacturing, if
required). Even efﬁcacy study design will be tricky. Efﬁcacy will
need to be established on the basis of prevention of acquisition of
the HIV infection itself and not on the basis of any immunological
correlate. Furthermore, virological or cellular correlates that have
proven useful in drug approvals for anti-retroviral drugs, may be
useful or important secondary endpoints of vaccine efﬁcacy studies.
Whether a vaccine can cause an infection to be transient, i.e., to be
cleared or aborted, might be able to be addressed with a virological
endpoint. However, immunological correlates will have to be
identiﬁed, if possible, in the conduct of human efﬁcacy studies (i.e.,
prevention of HIV acquisition in humans) and if they cannot be
identiﬁed, then the design of bridging or lot consistency studies,
etc., will remain a challenge. Similarly, the timing of conducting
such studies (after the successful efﬁcacy study is completed and
the correlate of immunity identiﬁed, if it can be) can be challenging
for a regulator to knowwhat to require of an applicant. Ideally, they
would be conducted before the end of the efﬁcacy study to speed
time to licensure after successful efﬁcacy results are seen, but this
may be infeasible for the reasons noted. Regulators should gain
agreement with clinical trial applicants on these points well in
advance of marketing authorization applications.
What is known, however, is that the immune response in an
infected individual does drive escapemutations to arise in the virus
with which s/he is infected, as well as reducing the viral load from
the peak at acute infection before the immune system can fully
respond to the infection down to a “set-point.”Mutations arise both
in known antibody epitopes and in known T cell epitopes [13,14]. In
many individuals, even effective neutralizing antibodies developand these drive viral evolution [15]. However, these neutralizing
antibodies develop rather late in the infection, after months of
chronic infection. The virus seems to always stay one step ahead of
the infected person's immune response against it. Thus, which
immune response might correlate with protection has not been
identiﬁed, and various scientists have differing opinions on this
matter. However, the fact that the immune system does drive viral
evolution and immune escape demonstrates the effectiveness of
some immune responses. In natural infections, the immune
response may be too little or too late, but vaccination might be able
to tip those scales in favor of the immune system.2.4. Variability
Another scientiﬁc challenge is that of variability. Strain vari-
ability is greater for HIV than any other viral infection. Infected
individuals do mount immune responses to their infecting strain,
but these immune responses do not clear the viral infection
completely. In many individuals, neutralizing antibodies arise, but
they arise late in the infection. As stated above, both T cell re-
sponses [14] and neutralizing antibodies [13] in the infected indi-
vidual do generate immune pressure causing the infecting virus to
mutate to escape this immune pressure. These escape mutants
seem to keep continually ahead of the immune response. However,
as a consequence, novel viruses are transmitted to others, ever
expanding the viral diversity. Consequentially, strains differ by
their relative sensitivity or resistance to antibody-mediated viral
neutralization. Also, there are a variety of routes of transmission
against which onewould like an HIV vaccine to protect. Populations
vary in their degree of risk of exposure and infection and whether
or not the degree to which a vaccine might be protective against
occasional and unpredictable exposure (e.g., general population) or
against relatively frequent exposure [e.g., discordant couples or
commercial sex workers (CSW) working within populations with
high prevalence] could be variable.2.4.1. Viral genetic or strain variability
HIV-1 consists of fourmajor types (M, N, O, and P), each of which
represents an emergence of HIV in humans from SIV of chimpan-
zees; thus, having occurred on four separate occasions [16]. Within
the main group, there are sub-types or genetic clades grouped into
six sub-types (A, B, C, D, F, and G) and numerous circulating re-
combinant forms (e.g., A/E, A/G, B/C). In part this is due to the
relative lack of ﬁdelity of the HIV polymerase, as with many RNA
viruses. In part it is due to immunological pressure, or in the case of
those on anti-retroviral therapy, pressure to resist the therapy and
continue to replicate in the face of it. The meaning of this genetic
variability on immunological variability is unclear, as HIV has never
been “serotyped” per se, like many other viruses have. In part, this
is because it is so unclear what type of immune response is pro-
tective (antibodies or cells, systemic or mucosal, neutralizing or
non-neutralizing, against which viral protein, etc.). As a result,
some vaccine candidates or regimens strive for clade-matching to
the region or population in which studies will be performed,
whereas others have attempted to address global variability with a
multi-clade or mosaic/consensus approach. Likewise, some candi-
dates have been focused on the envelope glycoprotein and others
have taken a multi-genic approach. It remains unclear which will
be needed for success. Thus, when regulators review a clinical trial
application (CTA), they should evaluate which approach is being
taken and expect the applicant to justify their approach in some
reasonable manner, e.g., providing immunology data that scientif-
ically support that the approach might achieve its aim.
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antibody neutralization
It was observed in the early 1990's that some strains of HIV
seemed much more resistant to antibody-mediated neutralization
than others [17]. Neutralization assays were developed over the
course of the 1990's and the 2000's to become better able to
distinguish between these differences. To date, no vaccine candi-
date or regimen has been successful at eliciting broadly neutral-
izing antibodies against the toughest-to-neutralize strains, despite
the fact that such antibodies do develop in some infected in-
dividuals. Efforts are underway to rationally design immunogens
capable of eliciting broad neutralizing antibodies. In the meantime,
such broadly neutralizing antibodies, recombinantly made into
monoclonal antibodies, are being explored as research reagents and
for clinical use. Importantly, to aid distinguishing the ability of
various sera, either from infected individuals or from vaccinees, or
monoclonal antibodies to neutralize various strains of HIV, a tier-
based ranking system was devised [18]. Strains of HIV are desig-
nated as being “Tier 1” if they are relatively easy to neutralize by
many antisera. “Tier 2” strains are more difﬁcult to neutralize and
may only be recognized by a few, more potent or broader antisera.
Often, there may be good recognition by an antiserum or antibody
of strains within a clade, but signiﬁcantly less across clades. Even
within clades, there is signiﬁcant variability by antisera to recog-
nize strains. The most potent and broadest of the new generation of
monoclonal antibodies can neutralize across clades to a consider-
able extent [19e23]. Regulators may need to consider the existing
human clinical immunogenicity data (as well as animal data) for a
vaccine candidate or regimen, which is expected to elicit anti-
bodies, for which they are reviewing a CTA for an efﬁcacy trial (or
advanced phase trial) to evaluate the ability of that regimen to elicit
antisera that will recognize the predominant clade of strains in
their country or region. While the regimen may not elicit broad
neutralization, the applicant should have evaluated this aspect and
should provide information in this regard for regulatory review, in
the cases of regimens expected to elicit antibodies.
Additionally, non-neutralizing antibodies can have positive
impact on killing infected cells or preventing infection of new cells.
These functions have been recently reviewed [24]. If the applicant
proposes a mode-of-action through such non-neutralizing anti-
bodies, they should provide evidence that their candidate vaccine
elicits them (either from animal studies or early human trials or
both).
2.4.3. Variability in route of transmission
HIV can be transmitted sexually by penile exposure (hetero-
sexual or MSM), vaginal exposure (heterosexual), or rectal expo-
sure (MSM or heterosexual in women), as well as intravenously
(Intravenous Drug Users/People Who Inject Drugs, unsafe blood
supply, or tainted needles/needle sticks) or frommother to fetus or
neonate intrapartum, peripartum, or post-partum during breast-
feeding. Depending on the route of transmission, one could envi-
sion that it may be easier or more difﬁcult for a vaccine to protect
against infection. Similarly, different types of immune mechanisms
may play a role in protection against different routes of trans-
mission, e.g., mucosal immunity vs. systemic immunity. One could
argue that in the case of intravenous exposure, it may be easier to
protect (robust antibody response in blood stream immediately “on
the scene”) or more difﬁcult (entry bypasses normal immune
mechanisms and provides ready access to target cells for infection)
than other routes of transmission.Whether this variability in routes
of transmission will impact vaccine efﬁcacy remains unknown.
Certainly, the amount of virus in the exposure inoculum is expected
to vary by route of exposure. The impact of this fact on whether a
vaccine will protect some populations with lower exposure dosesand not those with higher exposure doses is concerning. Consid-
eration will need to be taken by regulators regarding whether to
require different efﬁcacy trials in each population or enrollment in
the same efﬁcacy trial of various populations, or whether bridging
into various populations might be considered upon completion of a
successful efﬁcacy trial in one or more populations. Likewise, the
uniformity or variability of the population to be enrolled (all by
similar or same route of exposure or enrollment for risk by various
routes) should be justiﬁed by the applicant and that justiﬁcation
should be evaluated by the regulator.
2.4.4. Variable epidemiology
Some scientists have suggested that the modest efﬁcacy seen in
the RV144 study (described in the companion review) was as a
result of the low incidence of HIV infection found in the general
population in Thailand of those enrolled in the study. They have
further suggested that success might not be recapitulated in a
higher risk population (e.g., the general population in sub-Saharan
Africa, discordant couples, CSW in high prevalence settings).
However, arguably, anyonewho becomes infectedwith HIV has had
a high risk exposure by deﬁnition. What is unclear is whether a
“high risk exposure” in the general population in Thailand resulted
as a lower viral load transmission (fewer viruses in the exposure
inoculum?) than would be a “high risk exposure” in the general
population in some countries in sub-Saharan Africa (more viruses
in the exposure inoculum?). It certainly could be easier for a vaccine
to protect someone from a lower inoculum than a higher one. In
most cases of sexual transmission, infection appears to be estab-
lished by a single or nomore than a few viruses, based on studies of
viral diversity in acute infections [25,26]. It is nonetheless unclear
whether this variability in HIV prevalence in different populations
makes a difference for efﬁcacy of a protective vaccine. Another
aspect of note is the risk per exposure. Populations in which more
encounters with HIV-infected individuals are likely per potential
exposure, the higher overall risk for infection. Evidence from NHP
studies with repeated low-dose exposures permit estimates of
vaccine efﬁcacy per risky exposure. The combination of inoculum
size and repeated risky exposures may increase risk of infection in
higher prevalence populations; hence, such populations may need
a more potent vaccine in order to have efﬁcacy. A corollary to this
might be that a vaccine effective in a lower prevalence population
may not be effective in a higher prevalence population. However,
should discordant results be seen if multiple efﬁcacy studies (or in
sub-group analyses within a single one) are undertaken in different
populations with varying risks of exposure, regulators need to
consider what indication theymight approve for such a vaccine, i.e.,
in which populations might the vaccine be indicated in the label.
Regulators will need to consider also whether foreign efﬁcacy data
will support approval in their country, based on similarity or dif-
ferences of the risks and routes of transmission and clades of
circulating strains. It will be logistically impossible to recapitulate
efﬁcacy trials in every region/population type. What is scientiﬁcally
needed to support label claims remains unclear.
2.5. Vaccine-induced sero-positivity or sero-reactivity (VISP or
VISR)
Although this issue is less “scientiﬁc” and more a pragmatic one
with potential to result in social harms, it does raise a regulatory
challenge. In the United States, where more than 100 HIV/AIDS
vaccine clinical trials have been conducted, the U.S. NIH and the U.S.
Food and Drug Administration (FDA) have worked together to
ensure that labeling of licensed HIV test kits make clear that
participation in an HIV/AIDS vaccine study may result in a positive
or indeterminate test. So, such a result leads to the need to rule out
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with HIV, but is sero-positive or sero-reactive due to having been
vaccinated with an investigational vaccine candidate in a clinical
trial. Regulators in other countries may need to consider working
with the blood industry in their countries to raise awareness of this
possibility, as trials become more prevalent or large studies are
undertaken. Particularly when efﬁcacy studies are performed, as
they generally enroll subjects at some risk of HIV infection, means
to distinguish between sero-positivity or sero-reactivity due to
vaccination vs. due to actual infectionwill be needed. As many HIV/
AIDS vaccine candidates have become complex, containing many, if
not most, of the HIV proteins, antibodies may be generated against
most, if not all, of the antigens detected by test kits approved and
commonly used in your country. Consequently, it may be necessary
to rely on plasma RNA tests or other tests developed for the speciﬁc
purpose of distinguishing between vaccination and true infection
(DIVA), as no viral RNA would be present in the plasma of in-
dividuals who had been vaccinated in a clinical trial but was not
infected. Additionally, once a successful vaccine is demonstrated
and licensed, screening practices for HIV infections within coun-
tries that take up the successful vaccine may need to rely on plasma
RNA test kits rather than serological ones. A workshop on this
subject was held in 2012 and consultation of the meeting report
may be insightful.3
3. Vaccine candidates that may advance towards efﬁcacy
trials
The companion review outlined the outcomes of the completed
efﬁcacy studies performed to date. At present, there are no on-
going efﬁcacy studies. HIV/AIDS vaccine development must
continue with as much urgency as ever. Future efﬁcacy studies are
being planned with candidates similar or related to the modestly
successful regimen from RV144 and with candidates and regimens
that have shown promising safety proﬁles and immunogenicity
results in Phase 2A studies. These will be described below. Many
other candidates are in the pipeline, either in Phase 1 or 1/2, or in
preclinical development. Primarily, clinical candidates will be
described below. Regulators may receive CTAs for review to support
future clinical trials of some of these investigational candidates.
Existing data are, thus, summarized in this section.
It will be important for regulators to distinguish between early
phase trials they may be asked to review and efﬁcacy trials (either
pilot or pivotal). As explained in the companion review, regulators
should not focus on the nomenclature of the trial phase, but instead
focus on the principal aims of the study to either gain preliminary
data of safety and immunogenicity or to gain efﬁcacy data. For
those studies aimed at efﬁcacy, a distinction exists between those
intended to primarily generate hypotheses to be tested in pivotal
efﬁcacy trials and those testing such hypotheses, i.e., the pivotal,
licensure-supporting trials. Concurrence from regulators must be
gained for all phases and types of clinical trials of HIV/AIDS vac-
cines. However, regulators may wish to focus their energies on the
most careful review and consideration of the pivotal trials, the data
fromwhich they will subsequently be asked to review for licensure
or registration (marketing authorization).
3.1. Reprise of RV144 in South Africa
Because the RV144 regimen was designed speciﬁcally to match
the epidemic in Thailand, where the study was performed, plans to3 http://www.vaccineenterprise.org/sites/default/ﬁles/VISP%20Meeting%
20Report_FINAL_0.pdf accessed 10/14/2014.move forward with efﬁcacy testing in South Africa, where clade C
infections predominate, requires redesigning the candidate
regimen. A new ALVAC related to vCP1521, but expressing clade C
antigens, is in development by Sanoﬁ Pasteur (http://www.
sanoﬁpasteur.com/, accessed 10/14/2014, France and USA). They
have partnered with Novartis (http://www.novartis.com/, accessed
10/14/2014, USA), another major global vaccine manufacturer, to
develop the protein components, which will also be clade C.
Novartis also brings to the regimen a potentially more potent (and
possibly one that will result in more durable immunity) adjuvant,
MF59, which has an established safety proﬁle and is contained in a
licensed inﬂuenza virus vaccine. The plans for this new regimen of
ALVAC and MF59-adjuvanted protein may include incorporation of
additional boosts to extend the durability of the immune response.
In addition, due to evolving business relations between Novartis
and GlaxoSmithKline (http://www.gsk.com/, accessed 10/14/2014,
UK), other adjuvants may be considered, such as GSK's “Adjuvant
System” (AS##).
The plans for moving rapidly from Phase 1 to Phase 3 are sup-
ported by the P5 partnership, described in the companion review.
Initial studies are underway in South Africa and this may be
extended to also include Thailand. Thus, a regional approach to this
vaccine combination is being considered, with the ﬁrst place that
licensure would likely be sought being South Africa or southern
Africa, where clade C infections predominate. The extent of the
epidemic in this region supports the concept of seeking licensure
there ﬁrst. As the new regimen is highly similar or related to the
RV144 regimen, regulators will likely be asked to consider data
from RV144 to support licensure, should the new regimen also
prove efﬁcacious and safe. However, because all of the components
of the new regimen are in fact, new products, prudence warrants
conduct of Phase 1 studies initially. If safety and immunogenicity
proﬁles seem similar to those established for the RV144 regimen,
rapid advancement to Phase 3 seems likely. Due to the urgency to
ﬁnd and license a successful HIV/AIDS vaccine, all due haste should
be taken by the P5 to advance candidates related to those that have
shown modest efﬁcacy already. In fact, spokespersons for the P5
have stated that their goals are “to substantiate and extend the
RV144 results.” [27] Further goals include: to extend the results to a
higher risk population, to expand geographic scope, to enhance
level of efﬁcacy, to prolong duration of protection, to identify im-
mune correlates of protection and to continue to build a public-
private partnership for success. A successful outcome of an efﬁ-
cacy study in South Africa would substantiate the controversial
results of RV144. By enhancing the efﬁcacy or durability of efﬁcacy
with the new regimen and testing in a new region and population
with increased incidence of HIV acquisition, P5 hopes to extend the
RV144 results.
3.2. Phase 2A headed to phase 2B
There are some candidate vaccines that have successfully con-
ducted or are currently conducting Phase 2A studies. These candi-
dates are likely tomove forward to pilot efﬁcacy testing or Phase 2b
studies. The most advanced candidates include DNA priming with
poxvirus boosting or alternative (to ALVAC) poxvirus priming with
protein boosting or more complex regimens with DNA priming,
followed by poxvirus, then protein.
There has been considerable discussion about conducting pilot
efﬁcacy trials with adaptive trial designs, in which multiple
candidate regimens would be compared to a single placebo arm.
Futility analyses and analyses that would rank the various regimens
at interim timepoints in the study would permit “dropping” the
arms that are not likely to demonstrate efﬁcacy or which are more
poorly efﬁcacious and continuing the study with only the most
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efﬁcient, hinges on all candidate regimens being ready for efﬁcacy
testing at approximately the same time and that the study design
for efﬁcacy testing of each regimen be the same. It may be that such
a study designwould be conducted for scientiﬁc research purposes,
rather than strictly to support vaccine development leading to
licensure. Such a “research track” design is being considered. The
purpose would be, in addition to the gaining of scientiﬁc knowl-
edge and potentially, identiﬁcation of correlates to formally
hypothesis-test in subsequent studies, to down-select from various
potential candidate regimens, since animal models have not proven
predictive for this purpose, as down-selection with other drug
development often occurs through the use of animal studies.
3.2.1. Geovax
Geovax Labs, Inc. (http://www.geovax.com/, accessed 10/14/
2014, USA) has been developing products that are the result of the
scientiﬁc concepts of Dr. H. Robinson, formerly of Emory University
(USA), and Dr. B. Moss and colleagues of the NIH (USA). Dr. Rob-
inson developed DNA plasmid vaccine candidates to serve as a
prime in conjunction with the Modiﬁed Vaccinia Ankara (MVA)
vectors developed by Dr. Moss et al. The DNA plasmid vaccine
candidates include JS-2 and JS-7, along with JS-7 adjuvanted with a
GMeCSFeexpressing plasmid, which is in early development. JS-7,
the current lead candidate, expresses most of the genes of HIV, with
several inactivating mutations and/or deletions e gag, pro, RT,
gp120, gp41, tat, rev, and vpu from clade B. Of note however, is the
fact that the vaccine does generate viral-like particles, because the
expressed Gag polypeptide is myristoylated. The current lead MVA
vector, MVA/HIV62, expresses Gag, Pro, RT, gp120 and a truncated
gp41, also from clade B and also containing certain inactivating
mutations [28]. The DNA priming series is delivered at doses of
3 mg followed by MVA boosts at 108 PFU, although lower doses
have also been studied. Furthermore, different regimens have been
studied e either two DNA primes followed by twoMVA boosts at 0,
2, 4, and 6 months or 3 MVAs (without DNA priming) at 0, 2, and 6
months. Each of these regimens has strengths, as will be discussed
below in Section 3.2.1.2.
MVA is a poxvirus vector, like ALVAC, although the species of
origin is cowpox. Derived from a strain of vaccinia by serial passage
through chicken eggs, MVA spontaneously lost several genes as a
result of the species adaptation. As a consequence, MVA does not
propagate to any signiﬁcant degree in human cells and is not
believed to replicate in humans. So, like ALVAC, MVA is considered
to be a non-replicating (in humans) poxvirus vector. MVAwas used
in Germany as a smallpox vaccine in the 1970's, so there is
considerable human experience (>100,000 people) with the non-
recombinant virus, as a prophylactic vaccine. MVA has also been
licensed in the current era for use in biological-warfare-at-risk
populations like deployed military personnel, or has been stock-
piled for this purpose (for use in the general population at the time
of a biological attack).
3.2.1.1. Safety. Several clinical trials have been completed,
including a Phase 2A trial [29]. The most common adverse expe-
riences included pain and tenderness at the injection site [~75% of
recipients of DNA plasmid or placebo experiencedmild tomoderate
and ~25% (1st boost) and 68% (2nd boost) of recipients of the MVA
or placebo experiencedmild tomoderate (27%)]. Systemic reactions
were experienced at no more than moderate severity with the
majority experiencing no or mild reactions in recipients of DNA
plasmid, MVA boost, or placebo. Around 40% of subjects experi-
enced mild systemic reactions with the initial prime (DNA plasmid
or placebo), with decreasing percentages with each subsequent
inoculation. Among other types of adverse experiences, ~20% ofsubjects had mild experiences that were possibly-related to vacci-
nation and only ~2% of subjects had moderate experiences that
were possibly-related to vaccination. Less than 10% of subjects had
AEs that were probably or deﬁnitely-related to vaccination, with
the majority of those being mild. One SAE considered deﬁnitely-
related to vaccination was an allergic reaction starting within
15 min of receipt of the second dose of MVA. The symptoms
resolved within 2 h and no further vaccinations were given to this
participant. HVTN 065 [28], a Phase 1 study, demonstrated a similar
safety proﬁle. Approximately 20% and 50% of subjects experienced
mild pain and/or tenderness at the injection site following the DNA
plasmid primes or MVA boosts, respectively. Approximately 20% of
subjects experienced moderate pain and/or tenderness at the in-
jection site following the MVA boosts. When MVA was given as a
series of three inoculations, each was accompanied with nearly
100% of subjects experiencing pain and/or tenderness at the in-
jection site, the majority of these being mild in nature, and ~20%
being moderate. In comparison, among placebo recipients, only
mild pain and/or tenderness at the injection site was observed in
less than or approximately 50% of subjects. The proﬁles of mild to
moderate systemic reactions looked nearly identical between pla-
cebo recipients and vaccinees who received either the DNA-DNA-
MVA-MVA (DDMM) regimen or the MVA-MVA-MVA (MMM)
regimen, with perhaps slightly more reactions in those getting
MMM. It was stated that 7 AEs were probably or deﬁnitely-
attributed to vaccination and six of these were mild local re-
actions. The last of these was an individual who had a moderate
decrease in neutrophil count 14 days after the initial DNA priming
dose, which resolved and did not recur on subsequent doses. No
other laboratory abnormalities and no ﬁndings of abnormal EKG
ﬁndings were observed in this study, which could be attributable to
vaccination.
In theory, concern raised by clinical trials of new generation
smallpox vaccines (vaccinia grown in cell culture systems) of car-
diac complications, particularly myocarditis or perimyocarditis,
could be of issue with poxvirus-vectored vaccines and regulators
have expected increased scrutiny for such AEs. This theoretical
concern has not been observed so far with MVA.3.2.1.2. Immunogenicity. Immune responses in HVTN 205 [29]
were as follows, with the initial number being for the DDMM
regimen and the second number being for the MMM regimen:
 66% and 43% mounted CD4 responses;
 21% and 15% mounted CD8 responses;
 47% and 70% mounted antibodies against gp120;
 93% and 95% mounted antibodies against gp41;
 ~30% and ~65% mounted neutralizing antibodies against Tier 1
(easier-to-neutralize) viruses;
 ~15% and ~40% mounted neutralizing antibodies against Tier 2
(more difﬁcult-to-neutralize) viruses.
Thus, the DDMM regimen elicited higher percentages of re-
sponders with CD4 responses (p ¼ 0.01). However, the MMM
regimen elicited higher percentage of responders with antibodies
against gp120 (p¼ 0.001) and neutralizing antibodies against tier 1
(p ¼ 0.02) and tier 2 (p ¼ 0.02) viruses. Among responders, the
highest frequency CD4 cell responses were against Env (mean of
~0.1% and ~0.2%, respectively for DDMM andMMM) and Gag (mean
of ~0.2% and ~0.1%, respectively for DDMM and MMM). Only 2 re-
sponders to Pol were noted in the DDMM group. The magnitude of
CD8 cells was somewhat higher as follows: means of ~0.3% (DDMM,
against Env), ~0.2% (MMM, against Env), ~0.2% (DDMM, against
Gag), ~0.4% (MMM, against Gag), and ~0.09% (DDMM, against Pol).
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mean reciprocal titers of 6800 and 25,000, respectively for DDMM
and MMM, for a consensus gp140 (a truncated gp160 without the
transmembrane domain and cytoplasmic tail), 24,000 and 25,000
for gp41, and 29,000 and 29,000 for p24 (Gag). Mean titers were
similar with DDMM and MMM, though MMM trended to higher
means, particularly for gp120 and gp140. Serum IgA binding anti-
bodies were low in terms of responders, with almost none against
gp120, and less than 13% of responders with IgA in the serum
against gp41 or p24. Strong responses were seen to the immuno-
dominant gp41 epitope and antibody avidity was higher in the
MMM group.
The data published from HVTN 065 provides the following
immunogenicity information: CD4 responses were observed in 77%
of subjects receiving the DDMM regimen that was also used in
HVTN 205, i.e., the “full dose.” Whereas only 44% of subjects
receiving the MMM regimen mounted CD4 responses to vaccine
antigens. The magnitudes of these responses were between 0.07
and 0.17% of total CD4 cells. These CD4 responses persisted, and at
six months post-last-dose, 38% and 8%, respectively, in the DDMM
and MMM groups. CD8 responses developed in 42% and 17% of
subjects on the DDMM and MMM regimens, with magnitudes be-
tween 0.06 and 0.65%. Like the CD4 responses, the CD8 responses
persisted to six months post-last-dosewith 38% and 4% responders,
respectively, in the DDMM and MMM groups. It was stated that
responses did not differ between genders. Responses were directed
primarily to Gag and Env antigens.
Although T cell responses were better for the DDMM group, in
regards to antibody responses, the MMM group appeared superior.
96.6% of subjects receiving MMM seroconverted to HIV antigens as
assessed by the Abbott HIV-1/HIV-2 ELISA (these subjects were not
infected, but mounted an immune response due to vaccination).
73% of subjects receiving DDMM seroconverted. It was stated
however, that antibody responses were similar after the 2nd MVA
dose in both the DDMM andMMM groups, with boosting seenwith
the 3rd MVA dose. When measuring binding antibodies speciﬁc to
the vaccine antigen, the Env of ADA strain, 81% and 86%, respec-
tively, of subjects receiving DDMM and MMM responded.
Neutralization against another clade B strain, MN, was observed in
30% of subjects receiving MMM, with mean reciprocal titers (ID50)
greater than 50. In contrast only 7% of DDMM recipients developed
neutralizing titers, which were quite low.
3.2.2. EuroVacc
EuroVacc (http://www.eurovacc.org/, accessed 10/14/2014,
Switzerland and the Netherlands) has also been developing prod-
ucts based on a DNA prime, poxvirus-vector boost approach.
However, the poxvirus they have selected to use is NYVAC. NYVAC
was generated by intentionally deleting key genes from a vaccinia
strain, through recombinant DNA techniques, resulting in a
poxvirus vector similar to MVA in the sense of being essentially
incapable of replication in humans [30]. Arguably, NYVAC may be
somewhat more immunologically potent than MVA or ALVAC.
EuroVacc has conducted several trials, EV01 (testing NYVAC alone),
EV02 (testing DNA and NYVAC vs. NYVAC alone), and EV03 (also
testing DNA and NYVAC in different regimens) and in collaboration
with the HVTN, HVTN 078 (testing priming and boosting in various
combinations with Ad5 from VRC and NYVAC from EuroVacc).
Several more studies have been recently initiated by the HVTNwith
various EuroVacc products with the aim of conducting a Phase 2B
adaptive trial design, likely comparing NYVAC and protein to DNA,
NYVAC and protein. The proteins would be provided by Novartis
(see section 3.1 reprise of RV144 for further information). As a result
of the HVTN 505 and Phambili studies, combinations with Ad5 are
unlikely to move forward, regardless of potency.The DNA prime is given at 0 and four weeks, with the NYVAC
boosts at 20 and 24 weeks in the lead regimen, although other
regimens have been tested. Consideration is being given to a
regimen with 3 DNA primes and one NYVAC boost, so this might
become the lead regimen going forward. The DNA vaccine, DNA-C,
is delivered at 4 mg and expresses genes from a Chinese B/C re-
combinant virus, 97CN54, for the Gag, Pol, Nef, and Env proteins.
The NYVAC, NYVAC-C, aka vP2010, has been delivered at doses of
>106 and at 107.82 in EV01 and EV02, respectively and expresses the
same genes. The proteins planned to be used in future combina-
tions would be based on clade C and would likely be the same
proteins as those to be used in the study that would reprise RV144
in South Africa. The same NYVAC vector has been used to express
many other genes from agents causing other diseases, which have
been tested clinically and is also the basis for some licensed vet-
erinary vaccines. Another recombinant NYVAC vector is in devel-
opment, whichwould be capable of replication in humans, with the
thought being that this would improve potency further by having a
replicating vector eliciting responses like a live vaccine. This vector
is not as advanced and the following sub-sections will describe only
the replication-incompetent (in humans) NYVAC vector.
3.2.2.1. Safety. The safety of the DNA plasmid prime has been
demonstrated in EV02 and EV03. The EV03 study, although
completed, is not yet published. In EV02, all participants experi-
enced local reactogenicity following the DNA priming doses, mostly
pain and/or erythema at the injection site. All of these reactions
were mild, except for two subjects with moderate pain. No differ-
ences were noted between reactions following the ﬁrst or second
vaccination. Systemic reactions were noted in 57% of subjects
following DNA priming doses, mostly malaise and headache, while
at the same time, 35% of subjects who would later receive NYVAC,
but had received no vaccinations in the other arm of the study,
experienced similar events. These reactions were mostly mild, with
a few reactions of moderate malaise, myalgia, and/or headache.
Two events of malaise lasted for more than seven days. De-
scriptions of lab abnormalities, SAEs, and withdrawals related to
AEs are described in McCormack et al. [31].
The safety of the NYVAC vector has been demonstrated
expressing various antigens. The exact construct, NYVAC-C, has
been tested in EV01, EV02, EV03 and HVTN 078. HVTN 078 con-
tained regimens with Ad5 and is not summarized here, as thesewill
not advance. See Bart et al. (2014, 32).] In EV01, there were no
serious AEs nor severe ones (grade 3 or 4). Only one grade 2 local
reaction, induration, was observed after the second inoculation and
none after the ﬁrst. The most common local reactions were pain
(after either dose) and/or redness (after the 2nd dose) at the in-
jection site. The proportion of subjects experiencing erythema was
signiﬁcantly greater after the second than the ﬁrst immunization
(p < 0.002). Systemic reactions included the following: chills/rigors,
malaise, myalgia, headache, nausea. These were experienced quite
infrequently after the ﬁrst dose and after the second dose by less
than half of subjects, with malaise being the most frequent at 40%.
Laboratory abnormalities and other AEs are described in Bart et al.
(2008, 33).
In EV02, most subjects experienced pain and/or erythema at the
injection site following a NYVAC injection. The majority were mild
in severity. Four subjects experienced moderate local reactions of
pain, swelling, and/or itching. Two subjects experienced severe
induration or pain, respectively, after NYVAC either as a boost or
when given alone without a DNA prime. There were no signiﬁcant
differences in the pattern of local reactions following NYVAC given
as a boost or when givenwithout a prime. Likewise, the majority of
systemic reactions were mild. Four moderate events were observed
following NYVAC inoculation: headache, malaise, myalgia, and/or
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malities and further description of AEs may be found inMcCormack
et al. [31].
Like MVA, NYVAC vectors could also be associated with cardiac-
related AEs (myopericarditis) that were seen in clinical trials of
vaccinia produced in cell culture. Monitoring for such AEs, either
symptomatic or asymptomatic, have been included in various trials
of NYVAC vectored HIV/AIDS vaccine candidates. This is an
important issue for future regulatory oversight of these vaccines.
Overall, the regimen (2 DNA primes at 4 mg each followed by 2
NYVAC boosts at >106 TCID50) appears to be well-tolerated, with
most subjects experiencing some local reactions, mostly mild and
transient in nature, with mild pain at the injection site being the
most frequent experience. Mild malaise was the most frequent
systemic complaint.
3.2.2.2. Immunogenicity. In EV02, immunogenicity for one of the
regimens that may be the most likely to move forward, 2 DNA
primes followed by 2 NYVAC boosts, was 83% responders as
measured by ELISpot assay. For those who completed the full
regimen, the response rate was 90%. At peak response, two weeks
post-last-vaccination, ELISpot values ranged from 100 to 1100 SFU/
million cells. Almost half of responders (median response) had
ELISpot values exceeding 600. Responses to Env were the most
frequent with fewer than half responding to Gag or Pol and only
one responder to Nef. Fewer than half responded to Env and one
other peptide pool. All responders generated CD4 responses and
47% generated CD8 responses. The CD4 cells generated expressed 1
(~40%), 2 (~40%), or 3 (~20%) cytokines (gamma-interferon, IL-2,
and/or TNF-alpha). The CD8 cells expressed 1 (~25%), 2 (~35%), or
3 (slightly more than 25%) cytokines, or all 3 cytokines and CD107a
(~10%), a degranulation (killing) marker. Epitope mapping for re-
sponders to Env revealed an average of 4.2 peptides (range 2e8)
being recognized. There was a trend for women to respond better
than men. Prior vaccinia receipt did appear to impact the magni-
tude of responses to the DNA prime, NYVAC boost regimen, in men
(p ¼ 0.03) and women (p ¼ 0.05) at the peak time point. Approx-
imately half of responders retained T cells responses as long as one
year post-last-vaccination, with magnitudes that were not signiﬁ-
cantly different from earlier timepoints (p ¼ 0.09) [31,34].
Also at two weeks post-last-vaccination, 75% of subjects had
developed antibodies to the Env in the vaccine. However, these
responses were transient and only one subject had detectable
antibody responses six months after the last vaccination. The an-
tibodies generated in responders did not have neutralization
capacity.
In EV03 [35], in which three DNA primes and a NYVAC boost
were compared to the regimen described above (two primes, two
boosts), 94% of subjects responded at the peak time point in the
regimenwith three primes vs. 81% in the regimenwith two primes.
The peak magnitudes were a mean of 774 SFU/million cells (three
primes) vs. 398 SFU/million cells (two primes). Antibody responses
were not described for this study.
3.2.3. Karolinska Institutet DNA plasmid prime with USMHRP MVA
boost
Scientists at the Karolinska Institutet in Sweden have teamed up
with those at the USMHRP to develop a prime-boost regimenwith a
DNA plasmid vaccine, termed HISIV, expressing Env from clades A,
B, and C, Gag from clades A and B, and clade B RT and Rev and the
USMHRP MVA, termed MVA-CMDR, expressing Env from clade E
and Gag-Pol fusion protein from clade A. Not only is the regimen
heterologous for the vectors but also heterologous for the antigens
expressed. The regimen has included use of the Biojector® 2000 to
deliver the DNA plasmids i.m. (doses of 3.8 mg total of the 7plasmids) or i.d. (0.6 or 1 mg total). The DNA plasmids have been
given with or without protein GM-CSF at 150 mcg at the site of
injection of the plasmids, if given i.m., or by the s.c. route; or under
the site of injection of the plasmids, when given i.d.. TheMVA boost
is given at a dose of 108 PFU (generally i.m., although i.d. was also
explored with a dose of 107 PFU). One schedule of the regimen that
has been explored is 0, 1, and 3 months for the DNA plasmid primes
and month 9 (and in one trial, 21) for the MVA boost. Another
schedule explored in TaMoVac-01 was DNA priming at 0, 1, and 3
months with MVA boosting at months 7 and 10.5.
Trials have been conducted in Sweden and in the United Re-
public of Tanzania (Tanzania). Studies HIVIS 01/02 were Phase 1
studies. The HIVIS 03 study conducted in Tanzania was a Phase 1/2
study. Additional Phase 1/2 studies include: HIVIS 04, HIVIS 06,
TaMoVac-01 in Tanzania and HIVIS 05 and HIVIS 07 in Sweden.
Only the results of HIVIS 01, HIVIS 02, HIVIS 03, and TaMoVac-01 are
published at present [36e39].
3.2.3.1. Safety. In HIVIS 01 and 02 [36], in the arms that did not
receive the protein GM-CSF, which could confound the safety
proﬁle of the DNA plasmid prime, MVA boost regimen, the vaccines
were well-tolerated. Only four subjects experienced grade 2 AEs
following the DNA plasmid primes. All other AEs were mild.
Following the MVA boost, when given i.d., there were mild local
reactions, while when given i.m., there were more mild systemic
reactions. One subject experienced a grade 2 fatigue following the
MVA boost given i.m. No laboratory abnormalities were found
attributable to vaccine. ECGs were unremarkable.
In HIVIS 03 [38], of the AEs that were experienced within two
weeks of a priming dose, 40% occurred in those who received the
vaccine i.d., 36% in those who received the vaccine i.m., and 24%
occurred in those who received placebo. Most AEs were mild, with
eight events considered moderate (four in those who received the
vaccine i.d., three in those who received the vaccine i.m., and one in
a placebo-recipient). One event, a headache, was deemed probably
related to study agent, but this was in a placebo-recipient. Likewise,
the one SAE that occurred was in a placebo-recipient. The most
common events were headache (21%) and pain at the injection site
(12%). Of the AEs that were experienced within two weeks of a
booster dose, 77% occurred in vaccinees and 23% in placebo re-
cipients. All of these AEs were mild with the exception of an event
of moderate pain possibly associated with vaccination. The most
common event was pain at the injection site (30%). There was no
increase in severity of AEs on subsequent doses. 11 SAEs occurred
on study from time of dosing through the six months following the
last vaccination. Only two of these events occurred within two
weeks after a dose and only one in a vaccinee. A subject receiving
his/her last vaccination (2nd MVA), developed hematemesis,
considered unrelated to vaccination. The remaining nine SAEs
occurred outside the window of two weeks post-inoculation and
included: injury in a motor vehicle accident, fainting, ﬁssure in ano,
mild head injury, musculoskeletal chest pain, epistaxis, acute
gastroenteritis, paralytic ileus and hemoptysis. Two were consid-
ered probably not related and the rest unrelated to vaccination. No
laboratory abnormalities were noted and there were no remarkable
ECG results.
In the Phase 2a trial TaMoVac-01 [39], 120 subjects received
either placebo or 3 i.d. inoculations of DNA (plasmids pooled or
separated) at 0.3 mg per arm (right & left) at 0, 4, and 12 weeks
followed by placebo or 108 PFUMVA-CMDR i.m. (left arm) at 30 and
46 weeks. Most subjects regardless of regimen experienced some
local and/or some systemic reactions. The majority of these were
mild, with a few moderate and very few severe (local only) re-
actions. The most common (69%) local reaction was pain, including
the three severe reactions (1 following DNA, 2 following MVA). The
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that resulted in discontinuation of vaccination was in an individual
who experienced moderate itching and excoriations after a second
DNA inoculation. Three SAEs included two HIV infections and a
skull fracture complicated with osteomyelitis. Other severe AEs
were not SAEs nor associated with vaccination. Other lesser AEs
were not associated with vaccination, with the exception of
possibly-related events of altered menstrual cycles, herpes zoster,
herpes labialis, and allergic conjunctivitis. Infections were frequent
on study, including malaria, gastroenteritis, URI, and tonsillitis.
Anemia was frequently noted & subjects treated with iron sup-
plementation. Laboratory events were mostly mild with 12 par-
ticipants having events of grade 3 or higher. The majority of severe
events were asymptomatic neutropenia.
Overall, the vaccinations were well-tolerated in healthy adults
in Sweden and in Tanzania.
3.2.3.2. Immunogenicity. In HIVIS 01/02, following the priming
series, 30% of subjects developed T cell responses to vaccine anti-
gens as assessed by ELISpot to 1 peptide pools. Following booster
doses, 92% of subjects had T cell responses. 86% of subjects
responded to Gag, 65% to Env, and 59% to both Gag and Env. Only
one subject responded to RT. The best response rates following the
priming series were in those who received the DNA plasmid i.m.
However, following boosting, the i.d. and i.m. routes primed
equivalently. The addition of protein GM-CSF reduced the magni-
tude of the responses. Response rates and magnitudes were better
in those who received the booster dose i.m. than in those who
received it i.d. The mean response to Gag was 358 SFU/million cells.
Age was noted to inﬂuence response magnitudes with no high
responses in subject >40 years of age. Seven of 38 vaccinees sero-
converted as assessed by a routine HIV ELISA kit. By Western blot,
all seven reacted to Gag p24, one to Gag p17, and 1 to Env gp120. An
in-house ELISA assay revealed anti-Gag titers ranging from 50 to
10,200, but only one subject developed anti-Env (gp160) antibodies
of low titer, insufﬁcient to warrant conducting a neutralization
assay [36,37].
In HIVIS 03, response rates for ELISpot were similar following
the priming series, whether given i.m. or i.d., with the i.d. route
trending to higher response rates. Following the initial MVA boost,
responses rateswere consistently higher among those receiving the
priming series i.d. and response rates tended to drop off following
the second booster dose, evening out the response rates between
the two routes. Magnitudes of responses were in the low to mid-
hundreds of SFC/million cells following the ﬁrst boost. As with
response rates, magnitudes of responses tended to drop off
following the second MVA boost. While age did impact response
rates, evidence of prior vaccination (vaccinia scars) did not impact
the immunogenicity of the regimen. Subjects receiving the priming
series i.d. also tended to recognize more peptide pools, as many as 5
with a median greater than 3, than those receiving it i.m., who
responded to no more than 3 pools with a median of 2. Samples
were assessed by ICS after the second booster dose in 29 vaccinees.
86% developed CD4 and/or CD8 responses to Gag with 55% having
CD4 responses and 59% having CD8 responses. The response rates
and magnitudes by ICS did not vary between the priming routes.
Median magnitudes of CD4 ICS responses were on the order of 0.2%
against various Gag peptide pools (range 0.06e3.67). Likewise, for
CD8 responses, median magnitudes were higher than with CD4
with ranges from 0.1 to 1.15 against various Gag peptide pools.
Binding antibodies to gp160 were found in 21% of vaccinees after
the ﬁrst boost and in 90% following the second boost. Median titers
were the same whether the subjects were primed i.d. or i.m. (me-
dian 800 in both cases, with ranges from 200 to 3200 for i.d. and
200 to 6400 for i.m.). No one seroconverted based on a routinediagnostic ELISA following the ﬁrst boost, but all did following the
second boost. Neutralization was assessed following the second
MVA boost by the TZM-bl assay, in which none was found, and by
the PBMC assay, in which high responses rates were observed e
83% against an AE strain, CM235, and 72% against the clade B SF162
strain. However, only 31% of subjects had neutralizing activity
against another clade B strain, BAL. Responses rates did not differ by
priming route [38].
In TaMoVac-01, ELISPOT responders were frequent, whether the
DNA plasmid primes were given in pools (90%) or separated (97%).
The second MVA boosted the frequency of Env responses in at least
one regimen. The magnitude of responses to Gag and Env, respec-
tively, ranged from100 to 660 or 80 to 335 SFC/106 cells. Therewere
no obvious differences between regimens. Two placebo recipients
scored positive on either one occasion or sporadically (4/7 time-
points). ICS analyses revealed the following: CD4 responses be-
tween 41 and 67% for any peptide (Gag, Env) with highest
frequencies following the ﬁrst MVA. CD8 responses between 7 and
50% with highest frequencies clearly following the second MVA
(i.e., the second MVA boosted CD8 cells), as was seen with the
GeoVax products. Magnitudes of CD4 and CD8 responses generally
fell between 0.1 and 1% of total cells regardless of regimen. Mean
antibody titers were about 400 with ~90% of vaccinees responding.
The authors concluded that they could simplify the regimen to
three i.d. inoculations at a visit (0.6 mg) from the prior 5 (1 mg) of
DNAwithout deleterious effects on the potency of the regimen [39].
3.2.4. Chinese DNA plasmid prime, Tian tan poxvirus (vaccinia)
boost
Chinese scientists, Dr. Shao Y. and Dr. Ruan L., Chinese CDC, have
been working on use of the Chinese vaccinia virus (smallpox vac-
cine) strain, Tian Tan, as both a replicating and a non-replicating
vector, to express HIV antigens. The antigens are primarily clade
C or B/C (the predominant circulating clade in China). The non-
replicating vector has been tested clinically. They are also work-
ing on DNA plasmid vaccines and a heterologous prime-boost
approach. The Phase 2A study of this combination is ongoing or
recently completed in China and results are under analysis.
There are current plans to move towards a Phase 2B with some
combination regimen in China. Clinical trial data are not yet pub-
lished, although there are publications by Dr. Shao et al. on animal
studies with the various candidates.
3.3. Phase 1/2 potentially headed to phase 2A
In addition to the poxvirus-protein and DNA plasmid-poxvirus
regimens already described, another DNA plasmid prime-MVA
(poxvirus) boost regimen has been tested in Phase 1 or Phase 1/2
and may advance to Phase 2A. This candidate regimen contains a
clade C-expressing regimen developed by the South African AIDS
Vaccine Initiative (SAAVI) and tested by the HVTN in South Africa
and the USA.
3.3.1. SAAVI DNA plasmid prime MVA boost
SAAVI has developed a DNA plasmid prime-MVA boost regimen
expressing Gag, RT, Tat, Nef, and Env of a clade C strain originally
isolated in South Africa. The products were supported by NIAID
(USA) through regulatory support and contracts to manufacturers.
Unfortunately, the company that manufactured the MVA boost has
closed, so this product can no longer be manufactured there.
However, if an alternative manufacturer can be identiﬁed, progress
may resume. It is hoped that a South African manufacturer would
be able to tech-transfer and make these products. Meanwhile,
laboratory work continues on an improved version of the vaccine
candidate regimen at the University of Cape Town.
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same plasmid backbone, though a different construct, as the one
from the VRC that was used in HVTN 505 (see relevant safety and
immunogenicity data from sections 4.3.6.1 and 4.3.6.2 in the
companion review, respectively). In general, three priming doses
are given by needle and syringe rather than by Biojector, as VRC
used. Also, generally, two MVA boosts are given at doses on the
order of 109 PFU, but other regimens have been explored in
HVTN086. HVTN086 added a clade C protein boost from Novartis
(adjuvanted with MF59) to the regimen. It is not clear which
regimen would advance to further studies. The Phase 1 study re-
sults remain unpublished at this time.
3.3.1.1. Safety. In HVTN 073 [35], in information reported publicly
at conferences, the safety proﬁle was reported as favorable, with
only three of 48 subjects withdrawing from the study: one relo-
cated away from the study site, one experienced schizophrenia and
one developed a swollen tongue (it was not clear whether this was
in associationwith vaccination or what was the timing of this event
to know whether it was an allergic reaction to vaccination or not).
3.3.1.2. Immunogenicity. Likewise, in preliminary information re-
ported at conferences [40,41], the immunogenicity proﬁle was
favorable. With regard to T cell responses, 69% of subjects devel-
oped CD4 responses and 33.3% developed CD8 responses. Mean
response magnitudes of 0.02% of total T cells were observed, with
ranges from 0.008 to 0.07%. Median responses were stated to be
between 0.02 and 0.04%. The T cell responses were mainly directed
to Env (66.7% for CD4, 8.3% for CD8) and Gag (as high as 34.4% after
the ﬁrst boost, but falling to 15.2% after the second for CD4, 5.6% for
CD8), although there were better CD8 responses to Pol (25% for CD8
vs. 9% for CD4). CD4 cells were not boosted by the second MVA
dose, but CD8 cells were. T cell response rates were similar between
the USA and South African sites, although there were more re-
sponders among the USA subjects. The predominant cytokine
expression in CD4 cells was IL-2 and/or TNF-alpha, whereas the
predominant proﬁle in CD8 cells was interferon-gamma and/or
TNF-alpha. Antibody responses were not reported in these
presentations.
3.4. Phase 1
The pipeline for development of HIV vaccines continues to
expand at the earliest stages of clinical evaluation, with many
preclinical concepts remaining to enter the clinical pipeline. Some
of the preclinical vaccine concepts are incremental improvements
on existing products in the clinical pipeline, while others are
completely novel. New vector systems, new adjuvants, and new
delivery devices or systems are in preclinical development. In early
clinical development there are several familiar vector systems in
new combinations, e.g., alternative adenovirus-prime with a het-
erologous alternative adenovirus-boost, or delivered by a novel
delivery system, e.g., DNA plasmids accompanied with electropo-
ration. Other novel vector systems, e.g., Vesicular Stomatitis Virus
(VSV) or Sendai Virus, are also in clinical development. The
following sub-sections will describe some of the candidate vaccines
in clinical Phase 1. Depending on the safety proﬁles emerging in
Phase 1 and the immunogenicity, in terms of potency and the
ability to ﬁll a niche not ﬁlled by other candidate vaccines or reg-
imens, i.e., ﬁlling a novel immunological “space,” decisions will be
made by funders whether to advance these candidates further.
3.4.1. Electroporated DNA or DNA with cytokine adjuvants
At least two companies have developed electroporation devices
that are intended to improve the uptake of plasmid DNA vaccinecandidates in vivo. These devices may theoretically have slightly
more safety risks than delivery by needle and syringe or by Bio-
jector® 2000 delivery systems, which are already marketed. How-
ever, the safety proﬁle remains to be elucidated to determine this.
This may be balanced by the potential beneﬁt of enhanced potency
of the DNA plasmid vaccines delivered in conjunction with elec-
troporation. Whether the promise of this technology will be ful-
ﬁlled remains to be seen. Data to date suggests that electroporation
might not lead to the number of inoculations being decreased, but
that the immunogenicity may be improved or that dose-sparing
may be observed. Devices include those accompanying intramus-
cular injections and those accompanying intradermal injections.
Inovio Pharmaceuticals, Inc. (http://www.inovio.com/, accessed
10/15/2014, USA) is a developer of such electroporation devices,
which have been tested with a number of candidate vaccines,
including those to prevent inﬂuenza, malaria, and HIV, as well as
therapeutic products against cancer, which are in preclinical or
early clinical development. Their subsidiary, VGX International, Inc.
(VGXII, http://vgxii.com/, accessed 10/15/2014, USA), manufactures
the DNA plasmids used in conjunctionwith the device produced by
Inovio. The HIV DNA plasmid vaccine concepts are those of Dr. D.
Weiner from the University of Pennsylvania. Funding and/or clinical
trials support for HIV vaccine development have been provided by
NIAID and USMHRP.
Ichor Medical Systems (http://www.ichorms.com/, accessed 10/
15/2014, USA) is also a developer of such an electroporation device,
which has been tested with a number of candidate vaccines,
including those to prevent HIV, inﬂuenza and malaria, as well as
therapeutic products against cancer, immunotherapeutics, pro-
teins, and monoclonal antibodies. The Ichor device has been used
with a DNA plasmid candidate vaccine being developed by FIT
Biotech (http://www.ﬁtbiotech.com/, accessed 10/15/2014,
Finland), referred to as a Gene Transfer Unit or GTU®.
In addition to plasmid antigens, some developers, e.g., Dr.
Weiner (discussed above) or Dr. Robinson (discussed in section
3.2.1), are testing DNA plasmid candidate vaccines adjuvanted with
cytokines expressed on plasmids and injected simultaneously with
the DNA plasmid vaccines. Such cytokines include interleukin 12,
interleukin 15, and GM-CSF, among others. Funding and clinical
trial support have been provided by NIAID, USA.
3.4.2. Electroporated DNA with cytokine adjuvant prime with VSV
boost
Profectus Biosciences, Inc. (http://profectusbiosciences.net/
accessed 10/15/2014) has also developed DNA plasmid vaccines
adjuvanted with a plasmid expressing IL-12. Furthermore, they
have developed novel vectors based on Vesicular Stomatitis Virus
(VSV). The VSV concept was originated by Dr. J. Rose of Yale Uni-
versity. Dr. Weiner (mentioned above in section 3.4.1) has also
collaborated with the scientists at Profectus on DNA plasmid vac-
cines and cytokine adjuvant plasmids. Funding and clinical trial
support has been provided by NIAID and IAVI. Information on the
ﬁrst-in-human study can be found in Fuchs et al. [42].
3.4.3. Novel adenovirus serotypes with MVA vector in primeeboost
combinations
Dr. D. Barouch, Beth Israel Deaconess Hospital and the Ragon
Institute of Harvard University, USA, has been developing prime-
boost combinations based on heterologous rare-serotype (e.g.,
type 26 or 35) human adenoviruses or adenovirus in a heterologous
prime-boost combination with MVA. The individual vectors have
been tested independently in Phase 1 and themost likely candidate
regimen to advance further is an Ad26 prime-MVA boost combi-
nation. The Phase 1 results are published [43e45]. The choice of Ad
serotypes was based on seropositivity rates being low in human
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models. His corporate partner in the development of these prod-
ucts is Crucell (http://crucell.com/, accessed 10/15/2014, the
Netherlands), with funding from NIAID, USA. Dr. Barouch also re-
ceives funding from the Bill & Melinda Gates Foundation though a
Collaboration for an AIDS Vaccine Discovery (CAVD) grant.
Other serotype adenovirus vectors are in preclinical develop-
ment and they are based on serotypes derived from chimpanzees,
such as chAd6 and chAd7 (Dr. H. Ertl, University of Pennsylvania,
USA) and chAd3 and chAd63 (collaboration between Okairos,4 Italy,
and the VRC, NIAID, USA). Other rare human serotypes, such as
Ad35, Ad28, etc. have been tested, even clinically (Ad35), but it is
likely that these will not advance further as they appear to be less
potent.3.4.4. Replicating adenovirus vector
PaxVax, Inc. (http://www.paxvax.com/, accessed 10/15/2014,
USA) is developing a replicating adenovirus type 4 vector. Discov-
ery work on this concept has been performed by Dr. M. Robert-
Guroff (NIH, USA), who originally collaborated with Wyeth
Research, USA, which developed the vector system based on their
oral Ad4 and Ad7 vaccines previously licensed for use by the United
States military (Wyeth no longer makes these vaccines, and has
subsequently been purchased by Pﬁzer). A Phase 1 study is un-
derway comparing delivery by oral, tonsillar, and intranasal routes.3.4.5. Other replicating and non-replicating vectors
There are other replicating vector approaches in development.
The concept of a replicating vector is to trade on the beneﬁts
afforded with a live, attenuated vaccine, but without using live,
attenuated HIV, which would not be safe. By expressing HIV pro-
teins in a viral vector that replicates in the vaccinee, the endoge-
nous expression and ampliﬁcation of expression through
replication, along with limited spread of the vector, may achieve a
similar effect as infection, without the risks. For example, as
described above in section 3.2.3, the Chinese CDC has a replication-
competent Tian Tan (vaccinia) vector.
Other vectors not yet in the clinic or in initial studies, but worth
mentioning and under development by IAVI include Canine Dis-
temper Virus, Sendai Virus (this clinical study initiated in the fall of
2013, though results are not yet published), and Adeno-Associated
Virus (AAV, developed by Dr. Phil Johnson, Children's Hospital of
Philadelphia, USA and expressing a monoclonal antibody rather
than an antigen gene). Sendai virus (not as a vector) has been tested
clinically by Drs. J. Hurwitz and K. Slobod (St. Jude's Hospital, USA)
as a vaccine against parainﬂuenza virus 3, so there are some pre-
liminary safety data on this virus as a vaccine or vector. AAV has
been tested clinically expressing various antigens by several com-
panies, mostly as a therapeutic agent, but IAVI's AAV vectors were
vaccine candidates.
Many other novel vectors, either as replication-competent or
non-replicating vectors, in preclinical development, are being
funded by NIAID and include vectors such as Listeria, rabies virus,
SV40, measles virus, and others. Both IAVI and NIAID are supporting
preclinical research on rhesus cytomegalovirus as an analogue
vector in the rhesus animal model. Translation of this concept to
use of human cytomegalovirus as a vector has yet to occur and may
be difﬁcult, as rhesus and human CMVs are different viruses.
Nonetheless, plans to move this concept forward exist.4 Okairos was recently acquired by GlaxoSmithKline: http://www.okairos.com/
ﬁles/ﬁle/GSK%20strengthens%20vaccines%20business%20with%20acquisition%20of
%20Okairos_29_05_13.pdf (accessed 10/15/2014).3.4.6. Mosaic antigens or consensus antigens
Another approach to improving the global applicability of
candidate vaccines is to incorporate T cell linear peptide epitopes
from strains of varying clades into an artiﬁcial construct that results
in a natural-looking protein, often functional, which is constituted
of natural epitopes, but which, in that order and arrangement of
epitopes, does not exist in any particular strain of HIV. This so-
called mosaic approach was intended to improve the breadth of T
cell responses by expressing in a single, two, or three constructs the
most common epitopes found in strains of every clade. Vaccine
candidates will likely move forward containing these antigens,
even though the concept of a strictly T cell-based vaccine is no
longer considered a viable approach to achieve efﬁcacy. At least one
vaccine candidate with mosaic antigens has already entered the
clinic. These mosaic antigens may also elicit antibody responses, if
the protein is functional (and most of these constructs do generate
functional proteins) and thus, folds properly to present conforma-
tional epitopes. But, the design was not innovated for the purpose
of antibody-generation, but really to expand the breadth of T cell
recognition with a single antigen representing multiple clades and
strains. The bioinformatics used to design these mosaic constructs
are well-described in Fischer et al. [46].
Some researchers, e.g., Dr. B. Haynes (Center for HIV/AIDS Vac-
cine Immunology and Immunogen Discovery, USA) and colleagues,
are also studying consensus antigens, which are also bio-
informatically determined to contain the sequences most closely
matched to an “average” strain of HIV. Consensus or “center-of-the-
tree” approaches attempt to minimize the sequence divergence of
the immunogen candidate from all known strains within a clade or
within the M group of HIV. These approaches all attempt to make a
sequence that is as closely related to all known strains as possible in
an effort to “average” out strain divergence and attempt to generate
a universal approach to a problem of diversity.
4. Adolescents
The tremendous uncertainties about which vaccine candidates
will prove to be efﬁcacious in humans has stymied the efforts of
many to advance efforts for the inclusion of adolescents in HIV
vaccine studies. While no one wishes to bring harm to adults, most
adults have the capacity to make their own informed decisions
about trial participation. Children, in contrast, have limited au-
tonomy and are recognized to require additional protections to
prevent causing them harm in clinical research. This desire and
necessity to protect children from clinical research is in sharp
contrast to the need to protect children with clinical research.
Without performing research with children included, one cannot
discern how children may respond differently. There are biological
and sociological reasons to expect differences, and some of these
have been reviewed elsewhere [47]. Both in the European Union
(EU) and the USA, legislation has been enacted to require de-
velopers to study how to appropriately and safely dose children
with medicinal products. This legislation is in recognition of the
imperative to protect children with clinical research into the right
ways to prevent or treat their diseases or conditions rather than the
current practice of using in children products that have only been
approved for adult use; without knowing the proper doses, or even
formulations, appropriate for pediatric use, because there are no
data in children to guide these decisions.
In many, if not most, parts of the world, adolescents are at
highest risk of acquiring HIV infections. The epidemiological sta-
tistics speak for themselves and therefore, adolescents should be
the target population for a successful vaccine, when one becomes
available. Like Human Papillomavirus vaccine (HPV) and Hepatitis B
virus vaccine, vaccination of children before they become sexually
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the optimal approach to protecting adolescents at high risk of
infection. It is for these reasons WHO held two consultations; the
ﬁrst, in Lausanne, Switzerland in 2004, which covered the inclusion
of women, adolescents, children, and diverse racial groups in HIV
vaccine studies [48] and the second, in 2006, in Gaborone,
Botswana, which focused on inclusion of adolescents speciﬁcally
[49].
In the current situation, the timing of when or whether to
include at-risk adolescents in efﬁcacy studies or to attempt to
bridge in the absence of validated immune correlates by perform-
ing a immunological bridging study after efﬁcacy is shown in adults
remains an even more daunting dilemma. However, HIV/AIDS
vaccine studies, whether efﬁcacy or safety and immunogenicity
studies, need to be performed in an adolescent population in order
to assure that the ultimate target population for vaccination can be
safely, effectively and ethically vaccinated once a safe and efﬁca-
cious vaccine has been discovered. The debate of how (and when)
best to do this continues. Regulators may be asked to consider
protocols that may include enrollment of individuals younger than
the age considered to be an adult in their respective country. The
cited meeting reports from the WHO consultations may aid in
consideration of the relevant issues.
5. Special considerations in trial design and efﬁcacy
endpoints
The conduct of efﬁcacy studies for HIV vaccines has become
increasingly complex as more knowledge has been gained from
scientiﬁc advances and from the efﬁcacy studies that have been
completed. Particularly, going forward, the success of other pre-
vention modalities, the improvement in availability in even the
most-resource limited settings of antiretroviral therapy for those
who become infected on study through their own risk behavior and
the development of a newwave of potential monoclonal antibodies
that will be studied for prevention will increase this complexity.
5.1. Trial design in era of circumcision, PEP, PrEP, microbicides, and
other prevention modalities
In the past decade, considerable progress has been made in
demonstrating the efﬁcacy of various prevention modalities in
various at-risk populations. To take male circumcision as an
example, three separate efﬁcacy studies conducted, respectively, in
Kenya, South Africa and Uganda, demonstrated 48%, 53% and 60%
reduction in HIV-acquisition in heterosexual men who were
voluntarily circumcised [50]. As a consequence, when enrolling
men in HIV/AIDS vaccine studies, it is appropriate and ethical to
offer circumcision to those men who are eligible to participate in
the study, but who are uncircumcised at baseline. In doing so,
though, researchers must expect approximately half of the in-
fections that might have occurred in the men enrolled in the HIV/
AIDS vaccine efﬁcacy study will be averted due to the preventive
efﬁcacy of circumcision. Thus, in deciding sample size and calcu-
lating expected event rates to determine efﬁcacy of the investiga-
tional vaccine, the measured rate of events in a population of
uncircumcised men can be anticipated to be halved and so, twice as
many previously uncircumcised men would need to be enrolled (if
all were to accept circumcision) to observe the same number of
events. In this way, sample size calculations must be adjusted to
account for all of the various prevention modalities that might be
introduced in the conduct of an HIV/AIDS vaccine efﬁcacy study,
because they are or are likely to become standard-of-prevention
and thus, reduce the event rate that would otherwise be ex-
pected, based on epidemiology in the study population. Whenregulators review CTAs for HIV/AIDS vaccine efﬁcacy studies, they
need to assess whether and how the clinical trial sponsor plans to
offer standard-of-prevention and how they have calculated the
impact of other prevention modalities on event rates, for the pur-
poses of establishing relevant sample size of their study.
Additionally, some of the prevention modalities are transitory in
their effect. While circumcision, once performed, will continue to
exert its protective effect thereafter, in contrast, use of Pre-
exposure Prophylaxis (PrEP) will only protect while it is being
taken. If a subject enrolled in an HIV/AIDS vaccine efﬁcacy study
decides to begin to use PrEP while on study, his/her risk will be
reduced by PrEP use. If, s/he is non-adherent to PrEP use, or dis-
continues it, then his/her risk of HIV acquisition will return,
assuming his/her behavior that puts him/her at risk is unchanged.
Determining the exact amount by which such non-continuous risk-
reductionwill occur in a study is unlikely to be able to be calculated
accurately. Thus, statisticians may need to make certain assump-
tions or model expectations in calculating sample sizes and power
calculations. In addition, it is paramount that information about use
of other prevention modalities be tracked over the course of the
study in order to assist in evaluating the data at the conclusion of
the study. Regulators reviewing CTAs need to assess whether these
aspects have been clearly addressed and how the use of other
preventions will be monitored in the HIV/AIDS vaccine efﬁcacy
study.
All trial protocols should include some aspect of providing risk
reduction counseling to all participants. This counseling should be
conducted in line with UNAIDS guidelines. In addition, HIV testing
is generally part of the protocol both to ensure enrollment of only
subjects who are HIV-seronegative at baseline and for monitoring
for incident HIV infections that occur while on study. This coun-
seling and testing approach is a successful prevention modality.
Another aspect to consider is which populations to enroll. It may
become impossible to consider conducting a study in discordant
couples, e.g., because treatment of the infected partner to prevent
transmission to the uninfected partner and/or PrEP for the unin-
fected partner should be able to be accessed while on study. Thus,
transmission rates should theoretically fall to near zero in discor-
dant partners afforded these other prevention modalities. What
used to be considered a prime population to enroll into HIV/AIDS
vaccine and other prevention efﬁcacy studies may no longer be
considered a useful population to enroll. Regulators should
consider the populations sponsors propose to enroll and the other
prevention modalities to which those populations now have access
or should be afforded on study.
Finally, when considering viral load and CD4 counts as end-
points in an HIV/AIDS vaccine efﬁcacy study, early initiation of anti-
retroviral therapy will censure data collected after it is initiated, as
it has such a profound effect on these parameters and any addi-
tional effect of vaccination will not be able to be disentangled.
Therefore, collection of information about when and what types of
anti-retroviral therapy is initiated in those subjects who become
infected on study is also crucial to the data analysis. A plan for how
these statistical analyses will be handled should be clear and reg-
ulatory concurrence on the analyses gained before they are
implemented.
5.2. Endpoints and futility analyses
Previously, slowing the progression of the disease or onset of
AIDS or reducing viral load, while maintaining CD4 counts, in in-
dividuals who became infected through their own risk behavior
after vaccination, were considered reasonable primary endpoints
for a prophylactic HIV vaccine efﬁcacy study. Those goals are no
longer primary in the development of an HIV/AIDS vaccine. Given
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RV144 study, the ability of other prevention modalities (discussed
above) to prevent acquisition of HIV infection, and the ethical
mandate in clinical trial design to improve on existing therapies,
the primary endpoint of an efﬁcacy study should be prevention of
acquisition of HIV infection. Of course, safety should also be a pri-
mary endpoint, although in some trials, it might be considered a
secondary endpoint.
Reduction of viral loads and maintenance of CD4 counts in vacci-
nees, who subsequently become infected (i.e., vaccine break-
throughs), should be considered as important secondary analyses.
Immune responses (a few targeted main assays) to vaccination and
efﬁcacy (prevention of acquisition) in particular subgroups might be
included among secondary endpoints. Social harms, as a speciﬁc type
of safety analysis, may be considered as a secondary or tertiary
endpoint in an efﬁcacy study. Other immunological assays could be
considered tertiary or exploratory endpoints. Of course, study design
and the aims of the study drive which analyses are primary, second-
ary, etc. and these comments shouldbe construedas advisoryonly for
general principles. As always, judgmentmust be used in determining
what is appropriate in given studies a regulator may be reviewing.
It is important when there are multiple endpoints considered in
a clinical trial that a clear rank-ordering of analyses be prospec-
tively deﬁned. Not simply primary, then secondary, then tertiary,
but rather, within the secondary endpoints, which analyses will be
considered ﬁrst and which subsequently should be pre-deﬁned. In
other words, secondary analyses should be rank-ordered. Because
of the potential confounding by multiple testing, if the most
important secondary analyses fail, then less important analyses
become less relevant or less convincing. In this way, labeling claims
can be supported by the most important endpoints that are most
credible statistically and meaningful clinically. Data from pilot ef-
ﬁcacy studies may guide decisions about the rank-ordering of
endpoints in pivotal efﬁcacy studies.
Also, while the general approach to a “per-protocol” analysis of
the primary efﬁcacy endpoint is to include only those subjects
enrolled in the study conﬁrmed to be uninfected at baseline and
who received all study vaccinations or placebo inoculations (or in
some cases, the priming series, but not necessarily the boost). A
more realistic view of vaccine efﬁcacy and an approach that most
regulators would want to see analyzed would be the modiﬁed
intent-to-treat (MITT) analysis of the primary efﬁcacy endpoint.
This would include all subjects enrolled in the study conﬁrmed to
be uninfected at baseline and who received at least one study
vaccination or placebo inoculation. This is to be contrasted with an
ITT analysis inwhich all subjects enrolled were included, regardless
of whether they were actually uninfected at baseline or received
any inoculations. For vaccine efﬁcacy studies, it is generally the
MITT analysis that is most relevant to judge vaccine efﬁcacy. The
per-protocol analysis generally is the “optimal” situation, but the
realistic situation that may reﬂect real world situations most
closely would be theMITT. A statistician should advise in individual
cases what is most appropriate.
Finally, considering the outcomes of the various vaccine efﬁcacy
studies that have been completed to date, it is crucial that a futility
analysis be planned. In order to be able to do this, interim analyses
under the purview of an independent Data Safety Monitoring Board
(DSMB) or Data Monitoring Committee (DMC) are required. As a
consequence, the study sample size should be adjusted to account for
the loss of power from interim “looks” at the efﬁcacy data. Several
journalarticlesdiscuss theseaspects ingreater statisticaldetail [51,52].
From a regulatory perspective, in review of a CTA, a regulator
should conﬁrm that these facets have been addressed prospectively
in the protocol. Sometimes, a precise statistical analysis plan may
not be included in the protocol, but rather provided prior tounblinding and analyzing data. If that is the trial sponsor's plan,
then agreement between the trial sponsor and the regulator about
the timing of submission of the ﬁnal prospective statistical analysis
plan in relation to the analysis of the trial should be gained prior to
initiation of the study. Obviously, if interim analyses are planned,
these must be planned well before the end of the study, so either
that statistical analysis plan (for the interim analyses) should be
provided in detail in the protocol, or a clear indication of the timing
of the planned interim analysis and the timing of submission of the
statistical analysis plan for the interim analysis should be agreed
upon in advance of the trial initiation. Statistical adjustments for
such interim analyses should be considered and also agreed upon.
5.3. Adaptive design
There is considerable interest in clinical trials to incorporate
adaptive design, which originally gained favor in cancer therapy
studies. One concept of this approach is that a study can be
designed to compare multiple therapeutic arms and as each
endpoint occurs, judgment made in favor or against a particular
arm of the study. In this manner, less therapeutically beneﬁcial
study arms may be halted early and more subjects enrolled in the
more beneﬁcial study arms. However, these are not the only ad-
aptations that can be made. In reality, any changes (adaptations)
made to the study design after a study has been initiated, but which
have been planned in advance (usually based on reaching certain
contingencies), can be considered an adaptive design. Vaccine
studies permit certain adaptations to be made, but often, the study
will be fully enrolled and most participants will have completed
their vaccination series (or at least, their priming series, if there are
booster doses), well before a sufﬁcient number of endpoints are
accrued to be able to gauge whether or how to adapt the study
design. Nonetheless, some research studies (non-licensure-
enabling) are being planned with the intent of taking an adaptive
design approach. More information may be found in the article by
Gilbert et al. [51]. It is possible that regulators may be more
accepting of use of adaptive trial designs in non-licensure studies,
but may expect more rigor or use of more traditional statistical
approaches in pivotal licensure trials. Sponsors should discuss
these issues with regulators in advance of execution of any statis-
tical plan and regulators need to consider their comfort level and
willingness to accept an adaptive trial design for regulatory
decision-making. In the end, the analysis of the trial results must be
credible and reliable, and hopefully compelling, for regulators to
base decisions with any conﬁdence or certainty.
5.4. Correlates analysis
Future efﬁcacy studies should be planned and designed with an
aim to collect the correct samples at the correct timepoints, pro-
cessed and handled in the correct manner, and stored stably, to
permit a correlates analysis at the end of the trial, should efﬁcacy be
observed. HVTN 505 (described in the companion review) was
designed and planned in such amanner, although unfortunately, no
efﬁcacy was observed in that study. Nonetheless, deﬁning immune
correlates of protection is a top priority for efﬁcacy studies of HIV/
AIDS vaccines. Although many vaccines have been licensed suc-
cessfully without correlates, for the reasons discussed in Section
2.3, as well as the discussion about bridging to an adolescent target
population (Section 4), it is highly desirable to identify immune
correlates of protection for HIV/AIDS vaccines. In addition, because
initial candidates are likely to be nomore thanmodestly efﬁcacious,
knowing what immune correlates are may permit the rapid, iter-
ative development needed for highly efﬁcacious vaccine candidates
or regimens to follow.
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mechanisms, neutralizing antibodies, non-neutralizing but protective
antibodies, mucosal immune responses, CD4 or CD8 cellular re-
sponses, even innate responses, sampling and planning for storage
and analysis is more complex than might normally be the case for
vaccines that act solely through a systemic antibody correlate. Some
samples may require large volumes of blood cells or samples taken
from anatomical sites that might require somewhat invasive pro-
ceduresandsuchsamplesmayrealisticallyonlybetaken fromasubset
of individuals during a large efﬁcacystudy. Unfortunately, there is no a
prioriway to knowwhichparticipantswill become infected to be sure
to collect such samples for those speciﬁc individuals. So, this compli-
cates planning for a correlates analysis further.
Regulators should determine what a sponsor plans to do to
support a correlates analysis in their efﬁcacy study protocol. The
design should ﬁt with the proposed mechanism of action of the
vaccine candidate. For example, if the proposal is that the vaccine
will act through non-neutralizing antibodies, then a variety of
immunological assays to measure such non-neutralizing but
potentially protective antibodies should be planned. Some of these
assays, like antibody-dependent cell-mediated cytotoxicity assay
(ADCC) or antibody-dependent cell-mediated virus inhibition
assay (ADCVI), are not as well developed and validated as a stan-
dard ELISA or neutralization assay may be. So, the protocol should
be clear on the validation status and thus, credibility and reliability,
of such assays, if they are intended to support regulatory decision-
making. If they are proposed as exploratory endpoints, then they
do not necessarily need to be validated, but if they are central to a
correlates analysis (rather than just exploratory), then more in-
formation about their performance parameters should be provided
for regulatory review. Although the ICH Q2 document on Valida-
tion of Analytical Methods is intended for lot release, rather than
clinical assays, consideration of the principles in the ICH Q2
document for quantitative methods should be given to clinical
assays that will be used to support licensure or bridging on the
basis of correlates.
Another facet that should be borne inmind is that by the time an
efﬁcacy study is completed, it will be a good four toﬁve years after it
was planned, if not longer. Many new immunological assays will
have been developed in the meantime. Some ﬂexibility to incorpo-
rate new assays into the correlates analysis should also be consid-
ered. Furthermore, an assay thatmaynotbe validatedat the time the
efﬁcacy study is initiated, may become validated by the time the
correlates analysis will actually be performed, so some ﬂexibility to
review and decide-upon certain assays before they are used in the
analysis, butwell after the study is under-way, shouldbe considered.
This may require agreements be put into place between applicant
and regulator at the onset of the study to leave someﬂexibility at the
outset, but gain concurrence before analyses are undertaken and
regulators are asked to review the resulting data.
6. Access issues when a successful HIV/AIDS vaccine is
developed
It would be ethically unacceptable at the completion of an efﬁ-
cacy study of a clearly successful vaccine candidate or regimen to be
unprepared for access to the safe and efﬁcacious vaccine by the
placebo-recipients of the study (and continuedboosters, if called for,
by the vaccinees), by the communities from which the study drew
participants, and by the countries where the study was performed.
Consequently, it is critical that study sponsors work with commu-
nities and countries to plan for access and for communities and
countries to demand that these plans be made, even before the trial
initiates, and implemented. While not a regulatory requirement,
regulators should be mindful, as members of communities andrepresentatives of their country, that such plans be in place, if not
incorporated into the actual study protocol (however, if the sponsor
plans to amend the study to vaccinate placebo-recipients at
completion of the study or to continue to boost vaccinees, then such
plans, albeit without the details of the planned amendment, should
be made clear to regulators before the initiation of the study, at the
time of the original CTA review). Additional aspects, including
considerations for adolescents and women, on this topic of access
were discussed at a number of WHO/UNAIDS consultations [53,54].
6.1. Planning for a partially effective vaccine
Considerable efforts have been undertaken to model in the
context of different epidemic settings the utility of a partially
effective vaccine. In each case, vaccines of modest efﬁcacy if
implemented in high risk groups with sufﬁcient coverage could
have a dramatic impact to curb the epidemic.
6.2. Planning for success
Because HIV vaccines are such a high risk venture for industry,
often (if not in all cases to date) they are more prepared for iterative
product development or for failure than to dare hope for success.
This perspective is supported by the relative lack of success in the
ﬁeld thus far, so it should not be surprising that industry (and other
researchers) would think and plan taking this perspective. How-
ever, when considering the appropriateness of the conduct of an
HIV/AIDS vaccine study, regulators should be prepared to consider
and question potential applicants whether they are prepared for
success in the following ways:
 do they have sufﬁcient doses of the vaccine to rapidly vaccinate
placebo recipients in the efﬁcacy trial who remain uninfected at
study endpoint, if the trial demonstrates moderate to high ef-
ﬁcacy? Do they plan to amend the study to permit vaccination of
placebo recipients subsequent to achieving the primary
endpoint of the study? If not, why not?;
 what are the planned timelines for scale-up to commercial
manufacture and provision of licensure dossier for review sub-
sequent to study outcomes being known (if scale-up was not
performed prior to the conduct of efﬁcacy studies)?;
 what are the planned timelines for additional Phase 3 studies,
such as consistency lot studies, bridging studies (e.g., to
adolescent populations) and large safety studies (if additionally
needed), necessary to support the licensure dossier? Also, when
(at the outset, during the review, or post-licensure) in the re-
view of the licensure dossier will such data be provided for
regulatory review? Do you agree with the proposal or do you
have the necessary regulatory framework or mechanisms in
place to accommodate the proposal?;
 what are the plans for access subsequent to licensure or regis-
tration in the communities in which the trial(s) was conducted?
Although this latter question is less a regulatory question and
more a public health question, the appropriate national au-
thorities should consider this question. For regulators, has the
correct populations been studied in clinical trials to permit the
access plans, e.g., trials in adolescents?
7. Conclusion: how should regulators be prepared?
Regulators facing the evaluation of a clinical trial application of
an HIV vaccine clinical trial, particularly Phase 2b and 3 studies,
have signiﬁcant challenges. In this and the companion review, ef-
forts have been made to frame the scientiﬁc issues and challenges
in terms of regulatory challenges. Key among these scientiﬁc
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survivors from whom immune responses might guide vaccine
development; the lack of an immune correlate of protection; the
lack of predictive animal models for vaccine protection; the high
degree of variability with regards to strains of HIV, immunological
responses, routes of infection, populations at risk and the associ-
ated epidemiology. Additionally, issues surrounding vaccine-
induced seropositivity (seroreactivity), inclusion of adolescents in
HIV/AIDS vaccine clinical trials, conduct of future efﬁcacy trials in
an era of changing and evolving standard-of-prevention, concepts
behind adaptive and other innovative trial designs (including
accompanying statistical issues and the need to analyze the data for
potential immune correlates of protection) and access to a suc-
cessful HIV/AIDS vaccine once one is discovered present challenges.
Manyof the challengesdescribedhereinhave, atpresent, noclear-
cut answer or speciﬁc “right” course to take. The answers to many of
these questions are “gray” or “hazy” and there may be a lack of
consensus about such answers. The HIV/AIDS vaccine ﬁeld itself
struggles with these challenges and international efforts such as the
HIV Vaccine Enterprise and various public/private partnerships and
networks, as well as the WHO, are always continuing scientiﬁc dis-
cussions on these challenges as more data emerge. Many of these
discussions are taken in as publicly transparent a fashion as possible.
Regulators are encouraged to take advantage of various fora for such
public discussions. Collaborations among regulators within/across
regions are encouraged by WHO, such as the African Vaccine Regu-
latory Forum (AVAREF) and the Developing Country Vaccine Regu-
latory Network (DCVRN), to foster regulatory convergence on
common topics and to foster common regulatory practices. Regula-
tors may also ﬁnd collaboration or consultation with independent
researchers in their owncountries or regions to beuseful for bringing
strong scientiﬁc principles to bear on regulatory matters. Regulators
need always put in context not only the scientiﬁc and technicalTable 1
Examples of available WHO and UNAIDS documents that may provide useful informatio
Documents related to production, control, non-clinical evaluation, standardization, &
Title, source and reference
Good Manufacturing Practices for Biological Products. WHO, Replacement of: Technica
Series (TRS) No. 822, Annex 1 (2015).
http://www.who.int/entity/biologicals/GMP_For_Biologicals_version_Post_ECBS.pdf?ua
WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles. WH
986, Annex 2 (2014).
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_commit
ISBN9789241209861-TRS986.pdf?ua¼1
Good Manufacturing Practices: supplementary guidelines for the manufacture of inves
pharmaceutical products for clinical trials in humans. WHO TRS No. 863, Annex 7 (
http://whqlibdoc.who.int/trs/WHO_TRS_863_(p1-p98).pdf?ua¼1
WHO Good Manufacturing Practices for active pharmaceutical ingredients. WHO TRS
Annex 2 (2010).
http://www.who.int/medicines/publications/TRS957_2010.pdf?ua¼1
Guidelines for National Authorities on Quality Assurance for Biological Products. WHO,
Annex 2 (1992).
http://www.who.int/biologicals/publications/trs/areas/vaccines/regulatory/WHO_TRS_
Guidelines for Independent Lot Release of Vaccines by Regulatory Authorities, WHO T
Annex 2 (2010).
http://www.who.int/entity/biologicals/TRS_978_Annex_2.pdf?ua¼1aspects of the application, but also integrate into their considerations
local laws, existing guidelines, and the needs of their country, which
will host the clinical trial. Finally, regulators in each country must
make their own decisions on clinical trial applications and licensure
or registration, but advice and public vetting of the challenges can
occur inmanysettings, so thatno regulator should feel theirdecisions
must be made in isolation.
This review also provides some information about candidate
vaccines that regulators may ﬁnd themselves evaluating CTAs for
efﬁcacy trials to be conducted in their countries. The most
advanced concept is the reprise of the RV144 regimen; however,
due to various reasons, the products that will be studied are
essentially new products. In addition, other poxvirus vectors, DNA
plasmid vaccines (with or without various adjuvants or novel de-
livery devices), other viral vectors and subunit protein vaccines
potentially with novel adjuvants are likely to be the subject of
future efﬁcacy trials. Because of the novelty of the products in
comparison to licensed vaccines (live attenuated or inactivated
organisms, conjugates), regulators may need to become more
technically prepared for this review. With this aim in mind, we
advise regulators to familiarize themselves with the various exist-
ing guidance documents and WHO publications, such as consulta-
tion reports, developed to assist them in this regard and which we
have compiled a list to aid them in ﬁnding. It's important that WHO
has been in collaborationwith other bodies to derive consensus and
provide guidance. Appendix 1 provides two tables for guidance and
reports, as examples, from WHO and UNAIDS (Table 1) and from
ICH, FDA, and EMA (Table 2) with associated weblinks to ﬁnd the
documents with ease. The majority of guidance provided are not
speciﬁc to HIV/AIDS vaccines, but most, if not all, concepts and
principles contained within them are as applicable to HIV/AIDS
vaccines as to any other. In addition, Table 3 (Appendix 2) sum-
marizes the regulatory challenges presented in this review.n to regulators.a
regulation
Topics covered/Issues discussed
l Report
¼1
As an annex to GMP for pharmaceuticals, this document
provides general guidance on the manufacturing, control and
testing of biological products for human use, from starting
materials and preparations, including seed lots, cell banks and
intermediates, to the ﬁnished product.
O TRS No.
tee/
General guidance onmanufacturing of pharmaceutical products
(some sections also applicable for vaccines, in certain subjects).
tigational
1996).
General guidance for manufacture of investigational
pharmaceutical products. Principles in document also
applicable to vaccines.
No. 957, Guidance on GMP for the manufacturing of active
pharmaceutical ingredients (APIs) under an appropriate system
for managing quality. The special guidance for APIs
manufactured by cell culture or fermentation is provided.
TRS No. 822,
822_A2.pdf
General guidance for National Regulatory Authorities (NRAs)
and National Control Laboratories (NCLs) on quality assurance
for biological products (including vaccines) to assure their
safety and efﬁcacy.
RS No. 978, General guidance to NRAs and/or NCLs for setting national
requirements and system for independent vaccine lot release.
Document also provides useful guidance to vaccine
manufacturers.
Table 1 (continued )
Documents related to production, control, non-clinical evaluation, standardization, & regulation
Title, source and reference Topics covered/Issues discussed
Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of
Biological Medicinal Products and for the Characterization of Cell banks. Replacement of Annex 1,
TRS No. 878. WHO TRS No. 978, Annex 3 (2010).
http://www.who.int/entity/biologicals/vaccines/TRS_978_Annex_3.pdf?ua¼1
Guidance to NRAs, NCLs and manufacturers on basic principles
and, in some cases, on detailed procedures, that are appropriate
to consider in the characterization of animal cells that are
proposed for use in the manufacture of biological products,
including vaccines. Document also provides useful guidance for
establishing and maintaining cell banks.
Guidelines on the Quality, Safety and Efﬁcacy of Biotherapeutic Protein Products Prepared by
Recombinant DNA Technology. Replacement of Annex 3 of WHO TRS No. 814. WHO TRS No. 987,
Annex 4 (2013).
http://www.who.int/biologicals/biotherapeutics/TRS_987_Annex4.pdf?ua¼1
Guidance to NRAs and manufacturers on the quality, nonclinical
and clinical aspects of rDNA-derived biotherapeutic protein
products for the purpose of licensing. Some aspects of
manufacturing and quality control in these guidelines may
apply to protein-based vaccine antigens made by rDNA
technology, although vaccines are not included in scope of
document.
Guidelines for assuring the quality and non-clinical safety evaluation of DNA vaccines. WHO TRS
No.941, Annex 1 (2007).
http://www.who.int/biologicals/publications/trs/areas/vaccines/dna/Annex%201_DNA%20vaccines.
pdf
Guidance on quality and nonclinical aspects of DNA vaccines
intended for use in humans.
Guidelines for the production and quality control of synthetic peptide vaccines. WHO TRS No.889,
Annex 1 (1999). http://www.who.int/biologicals/publications/trs/areas/vaccines/peptide/WHO_
TRS_889_A1.pdf
Guidance on the development, production and control of
peptide vaccines for use in humans and to ensure their
consistent safety and efﬁcacy.
Guidelines on Stability Evaluation of Vaccines, Adopted in ECBS 2006. WHO TRS No. 962, Annex 3
(2012).
http://www.who.int/entity/biologicals/vaccines/Annex_3_WHO_TRS_962-3.pdf
Guidance on how to evaluate vaccine stability. This guideline
applies to all vaccines against infectious diseases.
Report:
Scientiﬁc considerations for the regulation and clinical evaluation of HIV/AIDS preventive vaccines.
Report from a WHO-UNAIDS Consultation 13e15 March 2001, Geneva, Switzerland
http://www.who.int/biologicals/publications/en/VHIV01mar13.pdf
Important reference about regulatory issues and clinical trials of
HIV vaccines.
The meeting identiﬁed gaps that need to be addressed from a
regulatory perspective to ensure appropriate progress of HIV
vaccine development from basic research to human trials,
licensing and future application, with a special focus on needs of
developing countries with recommendations on
Standardization and Control of HIV vaccines, conduct of HIV
vaccine clinical trials.
Report:
WHO Informal consultation on characterization and quality aspect of vaccines based on live viral
vectors, Geneva, Switzerland, 4e5 December 2003.
http://who.int/immunization/research/meetings_workshops/viral_vectors_report_full.pdf
Report of discussions and recommendations on requirements
for developing appropriate quality, efﬁcacy and safety testing
for full characterization of vaccines based on live viral vectors,
requirements for the clinical trial approval and licensure, and
identiﬁed needs for the development and establishment of
appropriate reference materials to improve quality control, as
well as efﬁcacy and safety testing.
Report:
WHO Informal Consultation: Development of Viral Vectored Vaccines for HIV, Malaria, Tuberculosis
and other Indications, Geneva, Switzerland, 1e2 October 2013.
http://www.who.int/entity/immunization/research/meetings_workshops/Oct2013_viral_vector_
meeting_comments.pdf?ua¼1
Report provides context for vectored vaccines against various
diseases including topics that differ between using a vector to
immunize rather than the disease organism itself.
Considerations such as heterologous prime and boost and pre-
existing vector immunity are discussed.
WHO Guidelines on Transmissible Spongiform Encephalopathies in relation to Biological and
Pharmaceutical Products. WHO/BCT/QSD/03.01 (2003). http://www.who.int/biologicals/
publications/en/whotse2003.pdf
Guidelines on aspects to minimize the risks associated with the
use of vaccines, blood products and other pharmaceutical
products containing bovine-derived and human-derived
materials.
Report:
Report of a WHO Consultation on Medicinal and other Products in Relation to Human and Animal
Transmissible Spongiform Encephalopathies. Geneva, Switzerland, 24e26 March 1997.
WHO/EMC/ZOO/97.3; WHO/BLG/97.2. (1997)
http://www.who.int/biologicals/publications/en/BTSE97mar24.pdf
Report on preventive measures to minimize the risks associated
with the use of medicinal products and medical devices
containing bovine-derived materials.
Guidelines on nonclinical evaluation of vaccines, WHO TRS No. 927, Annex 1 (2005).
http://www.who.int/entity/biologicals/publications/trs/areas/vaccines/nonclinical_evaluation/
ANNEX%201Nonclinical.P31-63.pdf?ua¼1
Guidance and general principles of nonclinical evaluation of
vaccines, with particular attention being given to the regulatory
expectations for new and novel vaccines. Both prophylactic and
therapeutic vaccines for infectious disease indications are
considered in this document.
Guidelines on the non-clinical evaluation of vaccine adjuvants and adjuvanted vaccines. WHO TRS
No. 987, Annex 2 (2013).
http://www.who.int/biologicals/areas/vaccines/TRS_987_Annex2.pdf?ua¼1
Guidance on consistent and harmonized nonclinical testing
approaches to support the use of candidate adjuvanted vaccines
in all stages of clinical development and ultimately for
marketing authorization of the adjuvanted product. This
document covers adjuvanted vaccines used in both prophylactic
and therapeutic indications against infectious diseases.
(continued on next page)
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Documents related to clinical evaluation
Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO TRS No. 924, Annex 1
(2004)
http://www.who.int/biologicals/publications/trs/areas/vaccines/clinical_evaluation/035-101.pdf
Guiding principles for regulatory review for the purposes of
clinical trial approval and licensing, which apply to a broad
range of vaccines. Document serves as basis for setting or
updating national requirements, as well as for WHO vaccine
prequaliﬁcation. Also informs manufacturers on regulatory
expectations for clinical evaluation of vaccines intended for
global use and should be read in conjunction with Guidelines or
Recommendations for speciﬁc types of vaccines. (Currently
subject to revision; updated version will be available at the
http://www.who.int/biologicals)
Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. WHO TRS No. 850,
Annex 3 (1995)
http://apps.who.int/medicinedocs/pdf/whozip13e/whozip13e.pdf
General guidelines on clinical trials. The Guidelines are
addressed not only to investigators, but also to ethics review
committees, pharmaceutical manufacturers and other sponsors
of research and drug regulatory authorities.
Training manual on the critical regulatory function for vaccines: evaluation of clinical performance
through authorized clinical trials. WHO/V&B/03.12
http://apps.who.int/iris/bitstream/10665/84312/1/WHO_V-B_03.12_eng.pdf
Manual provides more details on the indicators for the
evaluation of clinical performance through authorized clinical
trials. It offers practical suggestions, references to useful
publications for NRAs.
Regulation and licensing of biological products in countries with newly developing regulatory
authorities. WHO TRS No. 858, Annex 1 (1995)
http://www.who.int/biologicals/publications/trs/areas/vaccines/regulatory/WHO_TRS_858_A1.pdf
Guidance for newly developing NRAs/NCLs that may have
limited resources to license and regulate biological products,
including vaccines. It describes the responsibilities of such
authorities and of manufacturers and provides references to
relevant WHO publications related to their structure and
activities.
Operational Guidelines for Ethics Committees that Review Biomedical Research.
TDR/PRD/ETHICS/2000.1
http://www.fercap-sidcer.org/publications/pdf/201202/FERCAP-16-WHO%20EC%20Operational%
20Guidelines.pdf
Guidelines intended to contribute to the development of quality
and consistency in the ethical review of biomedical research.
Targeted for use by national and local bodies, these guidelines
deﬁne the role and constituents of an ethics committee, and
detail the requirements for submitting an application for
review. The review procedure, plus details of the decision
making process are provided, together with necessary follow-
up and documentation procedures.
Good participatory practice guidelines for biomedical HIV prevention trials, second edition, 2010.
UNAIDS/10.E/JC1853E (English original, July 2010).
http://data.unaids.org/pub/Manual/2010/guidelines_biomedical_hiv_prevention_2010_en.pdf
Guidelines intended to provide trial funders, sponsors and
implementers with systematic guidance on how to effectively
engage with all stakeholders in the design and conduct of
biomedical HIV prevention trials.
Provides a framework for development of effective stakeholder
engagement programmes. Consideration of speciﬁc trial and
local contexts will dictate how the guidelines are best
implemented.
Ethical considerations in biomedical HIV prevention trials
UNAIDS/WHO guidance document. UNAIDS/07.28E/JC1349E (July 2007)
http://data.unaids.org/Pub/manual/2007/jc1349_ethics_2_11_07_en.pdf
Document for potential trial research participants, investigators,
research staff, community members, government
representatives, pharmaceutical companies, other industry
partners and trial sponsors, and ethical and scientiﬁc review
committees involved in development of biomedical HIV
prevention products and interventions, including HIV
preventive vaccines. It suggests standards, as well as processes
for arriving at standards and can be used as a frame of reference
from which to conduct further discussion at the international,
national, and local levels.
Useful Weblinks
WHO catalogue of international reference preparations
http://www.who.int/bloodproducts/catalogue/en/.
HIV related international standards and reference reagents,
which may be used in clinical trial assays.
UNAIDS: http://www.unaids.org/en/aboutunaids/
WHO-UNAIDS HIV Vaccine Initiative:
http://www.who.int/immunization/research/development/hiv_vaccdev/en/
Documents relevant to HIV vaccines research and development.
Other WHO-HVI/UNAIDS (HVI) publications regulators may wish to consider: Meeting reports from the consultations with the experts for
research and development of HIV vaccines on:
 Considerations regarding efﬁcacy endpoints in HIV vaccine trials: executive summary and
recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in
support of the Global HIV Vaccine Enterprise. Fruth U. Vaccine. 2009 Mar 23;27(14):1989-96
Efﬁcacy trial endpoints, trial design considerations
 Executive summary and recommendations from WHO/UNAIDS and AAVP consultation on: 'The
inclusion of adolescents in HIV vaccine trials', 16e18 March 2006 in Gaborone, Botswana.
WHO/UNAIDS/AAVP International Expert Group, Osmanov S. AIDS. 2007 Sep 12;21(14):W1-10.
Considerations regarding clinical trials of HIV vaccines in the
age range likely to be the target of public health campaigns, i.e.,
adolescents before or around the time they becoming sexually
active and thus, at risk of HIV infection.
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 Ethical considerations related to the provision of care and treatment in vaccine trials. Tarantola D,
Macklin R, Reed ZH, Kieny MP, Osmanov S, Stobie M, Hankins C. Vaccine. 2007 Jun
21;25(26):4863-74
Considerations regarding individuals who seek enrollment or
are enrolled into HIV vaccine trials and become infected on
study through risk behavior e ethics surrounding their care and
treatment, outside the objectives of the study itself.
 Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group
consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vac-
cines', 31 January-2 February 2006, IAVI, New York, USA. WHO/UNAIDS/IAVI International Expert
Group. AIDS. 2007 Feb 19;21(4):539-46.
Proposal to rapidly advance HIV vaccine clinical trials by
conduct of pilot efﬁcacy trials to prove concept of HIV vaccine
strategy/regimen.
a WHO, in collaboration with other bodies, are playing an important role in the area of HIV vaccines. This table includes WHO Guidelines and Recommendations
published in the Technical Report Series (TRS), as well as meeting reports from WHO and UNAIDS consultations, as examples of the sources where regulators may ﬁnd
useful information.
Table 2
Other Regulatory Guidance from the International Conference on Harmonisation, www.ich.org, USFDA, www.fda.gov, or EMA, www.ema.europa.eu.
Title, source and reference Topics covered/Issues discussed
General or Quality or Safety-related Documents
ICH Validation, Q2(R1)
Validation of Analytical Procedures: Testing & Methodology
http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html
Guidance pertains to the concepts and methodology
relevant to the analytical validation of methods of analysis,
particularly lot release assays and tests. These concepts may
also be used in validation of analytical methods used for
clinical trial samples, although the document is not written
from that perspective.
ICH Quality of Biotechnological Products topics Q5A through Q5E
http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html
Documents pertain to viral safety and validation, expression
of construct, stability testing, cell substrates and
comparability when changes are made in manufacturing of
biotechnological products, including vaccines.
ICH Q6B Speciﬁcations: Test Procedures and Acceptance Criteria for Biotechnological/Biological
Products
http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html
Guidance pertains to the lot release of biologicals.
ICH Q7 Good Manufacturing Practices Guide for Active Pharmaceutical Ingredients
http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html
Guidance pertains to GMP. Although it is aimed towards
commercial manufacturing, many aspects apply to
manufacturing of investigational vaccines as well.
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html
Although this guidance is aimed more towards the safety
testing of therapeutic proteins than vaccines, some concepts
may be relevant. The WHO guidance would supersede the
guidance in this document when there are conﬂicts
between them.
FDA GFI on Cell Substrates 2010
http://www.fda.gov/downloads/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM202439.pdf
Guidance pertains to the choice and evaluation to qualify
cell substrates and viral seeds for vaccine manufacture and
includes some discussion of TSEs.
FDA GFI: Considerations for DNA Plasmid Vaccines for Infectious Disease Indications 2007
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/
Guidances/Vaccines/ucm074770.htm
Guidance pertains to the quality and safety evaluations of
plasmid DNAs used as vaccines.
EMA Procedural Advice on Medicinal Products Intended Exclusively For Markets Outside The
Community Under Article 58 of Regulation (EC) No. 726/2004 in the Context of Co-operationWith
the World Health Organization (WHO)
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/
2010/02/WC500074039.pdf
Guidance pertains to how to obtain a regulatory review and
advice from EMA reviewers on biotechnological products,
including vaccines, which will not be marketed in Europe.
Documents Related to Clinical Evaluation
ICH E3 Structure & Content of Clinical Study Reports
http://www.ich.org/products/guidelines/efﬁcacy/article/efﬁcacy-guidelines.html
Guidance pertains to how clinical study reports should be
prepared for regulatory review. It may be used as a guide to
how clinical trials should be planned and conducted.
ICH E5 Ethnic Factors in the Acceptability of Foreign Clinical Data
http://www.ich.org/products/guidelines/efﬁcacy/article/efﬁcacy-guidelines.html
Guidance pertains to how to ascertain relevance of studies
performed in other ethnicities to your population.
ICH E6(R1) Good Clinical Practices
http://www.ich.org/products/guidelines/efﬁcacy/article/efﬁcacy-guidelines.html
Guidance pertains to the appropriate manner in which to
plan, review andmonitor, audit, conduct, and report clinical
trials, including ethics committee responsibilities.
ICH Clinical Trial topics, E8 through E11
http://www.ich.org/products/guidelines/efﬁcacy/article/efﬁcacy-guidelines.html
Documents cover topics from general considerations for
clinical trials to statistical issues and choice of control
groups/design, and includes pediatric studies.
(continued on next page)
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FDA GFI: General Principles for the Development of Vaccines to Protect Against Global Infectious
Diseases 2011
http://www.fda.gov/downloads/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM282995.pdf
Guidance pertains to how the USFDA would support the
review and development of vaccines of global relevance,
including HIV vaccines.
FDA GFI: Toxicity Grading Scale for Healthy Adult & Adolescent Volunteers Enrolled in Preventive
Vaccine Clinical Trials 2007
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/
Guidances/Vaccines/ucm074775.htm
Document provides a sample grading scale for adverse
events following immunization, including reactogenicity, to
be used in clinical trials.
FDA GFI: Development of Preventive HIV Vaccines for Use in Pediatric Populations 2006
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/
Guidances/Vaccines/ucm074775.htm
Guidance pertains to preclinical studies and clinical studies
in children for HIV vaccines.
FDA Clinical Trials Guidance Documents
http://www.fda.gov/RegulatoryInformation/Guidances/ucm122046.htm
Documents cover a range of topics pertaining to clinical
trials, including ethics review.
EMA Regulatory Page for Human Medicinal Products
http://www.ema.europa.eu/ema/index.jsp?curl¼pages/regulation/landing/human_medicines_
regulatory.jsp&mid¼
http://www.ema.europa.eu/ema/index.jsp?curl¼pages/special_topics/general/general_content_
000489.jsp&mid¼WC0b01ac058060676f
Links to documents on a wide range of topics covering the
regulatory procedures of EMA, which has responsibility
within the EU for evaluating marketing authorization for
vaccines made through rDNA technology. Second weblink is
speciﬁc to clinical trials.
Table 3
Summary of challenges relevant to regulatory evaluation of clinical trial applications for HIV/AIDS vaccines.
Topic Challenge
Unknown type and amount of immune
response to guide vaccine
development
 Due to a lack of human survivors (convalescents), of predictive animal models, & of a validated immune correlate of
protection, there is little compelling scientiﬁc evidence to guide vaccine developers as to what type or amount of immune
response to aim to achieve with a vaccine candidate or regimen
 Regulators should consider the type of immune response the applicant claims to be the mode-of-action of the product to be
studied & the data provided demonstrating that the product induces such a response; T cells alone are unlikely to achieve
efﬁcacy, but some combination of T cellsa & antibody-mediated effects may
 Protocols for efﬁcacy studies, pilot or pivotal, should include plans to identify a correlate of protection, including collection of
appropriate specimens, in order to gain some parameter(s) to use for bridging, consistency lot studies, etc., later in
development or post-licensure
Variability  HIV/AIDS is fraught with variability challenges
 Strain variability (multitude of clades, quasi-species)
 Immunological variability (sensitivity to neutralization or immunity)
 Varying routes of transmission/populations at risk
 Varying epidemiology between geographies, risk groups
 Will trials need to be duplicated in various populations, geographies? Regulators will need to consider this question
 Do vaccines need to be multi-clade or will each clade need its own vaccine? Applicants may take varying approaches, but it is
unknown which approach will be successful.
VISP/VISR  Some vaccines will elicit responses that will score as “positive” in HIV test kits (serological); need assays to be able to
distinguish infected from vaccinated (DIVA)
 May need to rely more on NAT than serological tests for diagnostics
Adolescents  Adolescents will be a prime vaccination target, so clinical trials enrolling adolescents are needed
 Regulators need to consider what adult data they will require before allowing adolescent trials to proceed &whether efﬁcacy
established in adults will be bridged to adolescents or whether adolescents should have efﬁcacy directly evaluated
Trial design in era of evolving
standards of prevention & care
 Recognizing that it is unethical to withhold standards of prevention&/or care from trial participants, as these standards evolve
with increasing availability of suitable methods/products, trials will need to be designed accounting for the impact these
standards will have on reduction of clinical trial endpoints, among other trial design & conduct issues
 Some methods will reduce HIV acquisition risk indeﬁnitely (e.g., circumcision) & some only transiently (while the prevention
methods are in use), further complicating data analysis & ascertaining contribution of vaccine to protection
 Regulators reviewing protocol should ensure that applicant has addressed these facets in said protocol
Endpoints  Protocols for efﬁcacy of preventive HIV/AIDS vaccines should include prevention of acquisition of HIV infection as a primary
endpoint
 Modulation of disease progression in those who become infected despite vaccination may be considered an important
secondary endpoint (in efﬁcacy protocols; could be co-primary)
 Safety & immunogenicity should be studied in all clinical phases
Analyses, incl. futility  Clarity in analysis plan on per-protocol, ITT, MITT analyses, sub-group analyses, hierarchy of analyses vis-a-vis claims to be
made
 Efﬁcacy trials should incorporate a futility analysis, so studies of non-efﬁcacious or enhancing vaccines can be halted as soon
as feasible; hence need for DSMB/DMC oversight
 Statistical adjustments for multiple looks at data need to be deﬁned in analysis plan
 Regulators should consider whether applicant has adequately addressed such issues in protocol & receive analysis plan for
review & comment before applicant performs analyses
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Table 3 (continued )
Topic Challenge
Adaptive Design  Adaptations to trial design or conduct can be prospectively planned & engaged depending on contingencies (e.g., change in
attack rate within trial due to evolving standards of prevention, changes due to outcomes of other trials likely to be completed
during the conduct of trial under review)
 Regulators need to concur with such adaptations in advance of their execution by applicants, either during initial review or in
amendment(s)
Correlates Analysis  Regulators should expect applicants to plan for & collect necessary specimens to conduct an analysis for correlates of
protection (or risk) in efﬁcacy trials
 Regulators need to consider how applicants will be expected to bridge efﬁcacy, if correlate of protection is not identiﬁed,
despite efforts to ﬁnd one or more
 Vaccines that act through different modes-of-action may have different correlates of protection
 Regulators should consider whether applicant has anticipated that by time efﬁcacy study is completed, new assay methods
will be available, so specimens should be collected & stored for future analyses
Access Issues & Planning for Success  Although access to a successful HIV/AIDS vaccine is not strictly a regulatory issue, regulators should review proposed efﬁcacy
protocols with a mind towards how applicant has planned for success, incl. partial success, e.g.:
 Will placebo recipients be vaccinated at end of trial after successful outcome?
 Will community from which trial participants were drawn or country in which trial was conducted have affordable &
sufﬁcient access to successful vaccine after licensure?
 Others
 Regulators may wish to communicate with relevant national agency responsible for public health/access to vaccines/
medicines
How Regulators Can Prepare  Familiarize themselves with what is and what is not known, in order to have scientiﬁcally realistic expectations &
requirements of applicants
 Familiarize themselves with available guidance documents, meeting reports, reviews summarizing scientiﬁc challenges &
regulatory expectations with eye towards what is or is not known
 Recognize that there are many scientiﬁc unknowns, so relative lack of expertise on HIV/AIDS vaccines by regulator does not
mean that regulator has to make decisions in isolation & with greater uncertainty than exists within the ﬁeld
 WHO provides various documents, capacity-building efforts, & fora for regulators in different countries to discuss issues
among themselves & with experts in HIV/AIDS vaccine ﬁeld
 Regulators & applicants are encouraged to avail themselves of the aid WHO provides
a CD4þ (helper) T cells are needed for antibody-generation.
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Documents that provide some useful information for develop-
ment and regulatory evaluation of vaccines in general and HIV
vaccines in particular
Appendix 2
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